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Abstract 
 
Background: Physical activity declines post-cardiac rehabilitation (CR) suggests the need for 
an exercise maintenance intervention. The study objectives were to assess (1) health-care 
resource utilization, (2) QALYs, and (3) intervention cost-effectiveness.  
Methods: A randomized controlled trial of post-CR participants allocated to: (a) exercise 
facilitator intervention, or (b) usual care. Participants were randomized and asked to complete a 
baseline and follow-up surveys.  
Results: Overall, 297 (16.7%) graduates consented (50.2% intervention), of which 276 (92.9%) 
were retained at the 26 week and 264 (88.9%) were retained at 52 weeks. At 26 weeks, there 
were significant differences in emergency department mean visits (0.33±0.71 [control], 
0.22±0.51 [intervention]) and hospitalizations (0.16±0.39[control], 0.07±0.28[intervention]). At 
52 weeks, interventional participants had higher hospitalizations (p<0.05). There were minimal 
differences in quality of life (QoL) means score and QALYs throughout the trial among groups. 
Conclusion: These results suggest that there was an early cost-benefit associated with the 
intervention from a societal perspective, but this was not sustained at 52 weeks. 
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1.0 Introduction 
 
Cardiac rehabilitation (CR) is a secondary prevention program designed to achieve multi-
factorial cardiovascular risk reduction. Despite evidence for the benefits of exercise for secondary 
prevention of cardiovascular diseases (CVDs), physical activity (PA) declines dramatically post-CR. 
There is a need for an intervention with broad reach to promote exercise maintenance in CVD patients, 
to optimize secondary prevention. 
A randomized controlled trial (RCT) of an intervention to increase PA maintenance is currently 
underway. An exercise ‘facilitator’ assists the transition of patients from structured, supervised 
exercise, to self-managed home- or appropriate community-based exercise programs in the 1 year post-
CR. The objectives of this thesis are to: i) compare cardiac-related health care usage in CR graduates 
receiving the exercise facilitator intervention versus usual care; ii) compare quality-adjusted life years 
(QALYs) in CR graduates receiving the exercise facilitator intervention versus usual care; and iii) 
assess the cost-effectiveness of exercise facilitation. It is hypothesized that those in the facilitator 
intervention will utilize cost-driving health care resources (i.e., hospitals and emergency services) less 
frequently than those receiving usual care and greater QALYs than the usual care group over the 1-
year time horizon. It is also hypothesized that the facilitator intervention will be cost-effective from 
both a societal and health care perspective over this time frame.  
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2.0 Literature Review 
 
2.1 BURDEN OF CVD 
 
CVDs are currently the leading cause of mortality worldwide 
1,2
, with coronary artery disease 
(CAD), a CVD characterized by plaque formation within the coronary vessels, increasingly prevalent 
since the 1990s
3
. Globally in 2008, approximately 17.3 million deaths were due to CVDs, of which 
42% were due to CAD
4
.  
Of those that survive a myocardial infarction, approximately 15% are readmitted within 30 
days of discharge, and almost 25% require repeat revascularization procedures
5
. With CAD mortality 
rates projected to increase to 10 million in 2030 from 7 million globally in 2005, more financial and 
healthcare resources will be required to control this disease
6
. 
2.2 MEDICAL CARE COSTS FOR CVD  
 
 According to a Conference Board of Canada report, an estimated $20.9 billion was attributable 
to CVD care costs in 2005, and this figure is expected to increase to $28.3 billion by the year 2020
7
. In 
the United States (US), direct cardiovascular care costs as of 2010 were $273 billion, with indirect 
costs close behind at approximately $195 billion
8
.  
In addition to North America, other countries such as India, China, the United Kingdom (UK), 
and Saudi Arabia have also seen increasing CVD care costs
9
. Annually, in 2005, an estimated €104.7 
billion was spent on CVD-related procedures in Europe
10
, $5.9 billion in Australia
11
 and approximately 
US$ 10 million in Saudi Arabia
12
. With scarce resources and financial constraints, there are many 
governmental and third-party administrators looking to allocate these financial resources to more cost-
effective approaches.  
Since CVD is a chronic disease, once coronary artery blood flow is restored there is a need to 
regress or stabilize the underlying atherosclerosis via secondary prevention
13
. Indeed clinical practice 
guidelines on secondary prevention have been issued by learned medical societies. According to the 
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US Preventative Services Task Force, the goals are lipid reduction, normalizing blood pressure, 
modification of lifestyle behaviour, while also providing patient support and education
14
. 
2.3 CARDIAC REHABILITATION  
 
CR is a chronic disease management program aimed at reducing cardiovascular risk. In 
Canada, the average program lasts from several weeks to a full year
15
, and in Ontario, the average 
program is 5 months with a frequency of two classes weekly
16
. According to the most recent standards 
by the British Association for Cardiovascular Prevention and Rehabilitation (BACPR), there are 7 core 
components of CR
17
. These are: lifestyle risk factor management, psychosocial health, health 
behaviour change and education, pharmacotherapy, medical risk factor management, long-term 
management, and audit and evaluation
18
. One of the chief elements of the health behaviour change 
component is exercise. Canadian guidelines recommend 30-60 minutes of moderate to vigorous PA on 
most, preferably, all days of the week for patients with CAD
19
.   
According to the most recent Cochrane meta-analysis, participation in CR is related to 
decreased long-term (≥12 month) cardiovascular mortality (OR 0.74; 95% CI 0.63-0.87) , and total 
mortality (OR 0.87; 95%CI 0.75-0.99) when compared to usual care
20
. Jolliffe et al. 
21
 had previously 
examined the effects of exercise-based versus comprehensive CR. Participants in exercise-only CR 
showed a decrease in total mortality (OR 0.73; 95% CI 0.54-0.98), which was not observed with 
comprehensive CR (OR 0.87; CI 0.71-1.05). However, cardiac mortality was reduced substantially in 
both the exercise-only and comprehensive CR groups (OR 0.69; 95% CI 0.51-0.94), (OR 0.74; CI 
0.57-0.96), respectively. CR has also been documented to decrease re-hospitalizations
22,23
,  improve 
risk factor control
20
, while enhancing quality of life (QoL)
24
. 
The beneficial effects observed from participation in CR arguably stem primarily from an 
improvement in cardiometabolic fitness. These improvements are the result of the effects of exercise 
training on cardiovascular risk factors, vascular biology, and the atherosclerotic process itself.  
Exercise training has been documented to reduce C-reactive inflammatory protein concentrations
25
, 
increase cardiovascular functional capacity
26
, decrease myocardial oxygen demand, maintain lipid 
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control
27
, have a blood pressure lowering effect, aid weight control, and improve insulin 
sensitivity
28,29
.   
Few CR programs have incorporated strategies to assist patients in making a successful 
transition from supervised to self-managed home- and/or community-based exercise. In most CR 
programs, long-term maintenance is addressed briefly or not at all. Effective transition to post-CR care, 
focused on maintaining and enhancing gains in levels of activity experienced during CR, would protect 
and augment the investment in exercise adoption. 
2.4 HEALTH ECONOMICS AND CARDIAC CARE 
 
 Healthcare resources are scarce, and with an increase in patient demand for CVD care, there is 
a need to allocate these resources in a manner which maximizes health benefits and minimizes 
opportunity costs (i.e., the cost of an alternative that has been foregone). Health economic evaluations 
help us allocate these scarce resources. Three economic evaluation methods are cost-effectiveness 
(CEA), cost-benefit and a cost-utility analysis (CUA)
30
. CEA focuses on the cost or input in an 
outcome measured in natural units (for example, an increase or decrease in hospital admissions) while 
a cost-benefit analysis reports outcomes measured in natural units in monetary values. Cost-utility is 
similar to cost-effectiveness, but varies in how the outcome variable is reported. Instead of using 
natural units, cost-utility combines QoL and time span, and reports outcomes in QALYs. QALYs are 
defined as a measure of health output that combines the increase in QoL over the duration a treatment 
or while a program is being administered. The concept of a CUA from a governmental or third-party 
holder is preferred over a CEA since the results achieved from this analysis can be used to compare 
different programs 
30
. These three analyses seek to maximize health gains in a given program, by 
assessing whether it is worthwhile compared to a standard program, and aid in decision-making. 
 As a result of limited healthcare resources, clinicians are under increased pressure from the 
government to adopt policies and programs that are more cost-effective 
31
. Compared to an unmanaged 
fee-for-service model, offering CR programs, which facilitate inter-provider coordination of care and 
optimal secondary prevention, can reduce healthcare costs 
32
.  
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A systematic review of CR economic evaluations by Wong et al.
33
 included 9 studies, 
governmental and societal perspective studies, which illustrated that implementing CR is cost-effective 
as the cost/QALY was in a reasonable willingness-to-pay (WTP) threshold. The WTP threshold is 
often used to decide whether the amount one is investing in a QALY or outcome is in an acceptable 
range. All summarized societal studies, in particular the study by Ades et al.
34
 found that CR is cost-
effective since there are reduced hospitalizations costs compared to other medical interventions [CR 
(US $ 4950/ Life-year gained (LYG)) and coronary artery angioplasty (US $ 126 400/LYG)]. In this 
paper, LYG was defined as the increase in life expectancy calculated by using previously-reported 
decreasing mortality rates attributable to CR
35
. The most recent governmental perspective study 
included in the review examined the effect of CR on dialysis patients
36
. It was found that CR was very 
effective, as the incremental cost-effectiveness ratio (ICER) was $13,887 per year of life saved in favor 
of CR. The ICER represents the additional cost for an outcome (QALY) when compared to another 
program or intervention. 
In two other studies that assessed total healthcare costs of CR components, and the cost-
effectiveness of implementing CR programs in EUROASPIRE III countries, CR was deemed very 
cost-effective 
37,38
. De Smedt et al.
38
 assessed the costs of different interventions (smoking cessation, 
cholesterol treatment and lifestyle intervention) to optimize CVD prevention in EUROASPIRE III. 
The majority of the European countries found all therapies to be cost-effective since much of the costs 
were below the $30,000 WTP threshold value. Dendale et al.
37
 studied the long-term effects of 
comprehensive CR on the risk of recurrent CVD complications and their associated health costs. It was 
found that since total health care costs at 4.5 years follow-up in the CR group was lower [€4,862 
/patient] than the usual care group [€5,498 /patient], CR was cost-effective.  
2.5 DECLINE IN PHYSICAL ACTIVITY POST-CR 
 
 The long-term benefits of CR lie in the patient’s ability to maintain their health behaviour 
changes, and most importantly PA, over the long-term. Numerous studies have reported that graduates 
are failing to maintain adequate levels of PA (150 minutes of moderate/vigorous physical activity 
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weekly)
39–41
 despite education and counselling in CR
42,43
. Willmer et al.
44
 compared how PA at one 
and five years post-CR varied in patients that had engaged in an exercise maintenance program versus 
those that had not. Regardless of their membership in an exercise maintenance program, both groups 
engaged in fewer minutes of PA (maintenance program at 1 and 5 years (140 and 120 minutes per 
week respectively), no maintenance program at 1 and 5 years (138 and 105 minutes per week 
respectively)), and less frequently met the recommended 30 minutes of PA per day.   
In another study by Stahle et al.
45
, graduates were randomized to either to CR or usual care and 
then followed 12 months post-program. Patients who were randomized to CR at 3 and 12 months post-
CR had a reduced exercise capacity [measured in Watts (W)] compared to those in usual care [CR 
group (120 W & 100 W at 3 and 12 months respectively]. In addition to exercise capacity, patient’s 
self-reported PA (self-reported on a scale from 1 to 7) had also decreased to similar levels as those who 
never attended CR (CR group (4.3 and 3.6 at 3 and 12 months post-CR respectively), usual care (3.8 
and 3.5 at 3 and 12 months post-CR respectively)). Overall, the literature suggests that only 38-56% of 
CR participants are adequately active 1 year after CR program completion
46,47
.   
2.6 EXERCISE FACILITATION POST-CR 
 
Given PA declines, interventions to increase PA levels post-CR have been tested. To our 
knowledge, there have been 10 published RCTs of interventions to improve exercise maintenance 
post-CR
48–56
; 8 of these RCTs have shown beneficial results
48–50, 53–56
. Interventions that improved PA 
levels or helped maintain CR induced benefits (e.g., improvements in cardiometabolic fitness), 
incorporated a mix of self-regulatory skills training on exercise planning;
54
 exercise consultation;
49
 an 
exercise diary and quarterly group meetings;
48
 a home walking program and daily activity log 
51
; 
written action and coping plans
55,56
; and self-monitoring of vital measurements, and pedometer-
measured PA with personal feedback.
50
  Only one study was undertaken in Canada; it did not improve 
exercise maintenance 52 weeks post-CR.
52
 
There are substantial limitations to the literature assessing interventions for exercise 
maintenance. One of the most critical limitations is the lack of an economic evaluation; previous 
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studies
48,51,54,57
 that have assessed interventions for increasing PA levels did not consider incorporating 
community resources for exercise to facilitate sustainability and affordability. 
A three-site, RCT titled Ecologically Optimizing Exercise Maintenance in Men and Women 
Post-Cardiac Rehabilitation: A Randomized Controlled Trial of Efficacy with Economics (ECO-PCR) 
was proposed to investigate the cost-effectiveness of an exercise facilitator intervention to increase 
long-term exercise maintenance in CAD patients post-CR. Given the components of previously 
successful RCTs that improved PA levels post-CR (e.g., exercise consultation, self-regulatory skills in 
exercise planning), the facilitator intervention aimed to assist the transition from CR, a supervised and 
structured program, to a home or community exercise program (i.e., Heart Wise Exercise programs; 
www.heartwiseexercise.ca). The ECO-PCR trial includes an economic analysis of the intervention as 
part of the RCT. Effectiveness of the intervention was defined as a decline in cost driving health care 
resources such as visits to the emergency department or hospital admissions; visits to a cardiologist or 
physician was seen as preventative as these do not pose a major financial burden as the emergency 
department visits or hospital admissions.  Effects of the intervention were analyzed to test whether it is 
economically viable, which may convince health policy-makers that the intervention should be 
implemented. 
There are three objectives to this thesis. The first objective is to compare how cardiac-
related health care resources (emergency department and hospital visits) were utilized among patients 
in the intervention compared to those in usual care. The second objective is to assess the impact of the 
intervention on QALYs, when compared to usual care. The third objective is to assess the cost-
effectiveness of implementing this intervention.  
2.7 CANDIDATE’S ROLE 
 
The candidate’s role in this study primarily involved follow-up assessments for the Toronto 
participants in ECO-PCR trial at the 52 time-point. This involved administering surveys, chart 
extraction, accelerometer data collection and assessment and documentation of vital sign 
measurements. Any out-of-range vital sign findings were documented and reported to the qualified 
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clinical investigator. The candidate also followed up with participants via mail and telephone to ensure 
each assessment was complete. Finally, the candidate undertook blinded data entry, as well as data 
cleaning and analysis related to this thesis.   
3.0 Methods 
 
3.1 DESIGN  
 
This study was a randomized (Appendix A), controlled, allocation-sealed, superiority study that 
aimed to evaluate the effectiveness of an exercise facilitator intervention on exercise maintenance and 
health care resource utilization. The trial was registered with clinicaltrials.gov (Identifier: 
NCT01658683), and was reported according to the CONSORT guidelines
58
. The study was funded by 
the Heart and Stroke Foundation for 5 years. The study protocol was also approved by Research Ethics 
Boards of participating hospitals and York University. 
 
3.2 PROCEDURE 
 
Potential participants were approached during their second last and last CR classes. Study 
coordinators explained the study to potential participants and obtained informed written consent 
(Appendix B) before any clinical data was collected.  
The study coordinator extracted from medical databases and charts, participant information 
about medical history, bloodwork, risk factors, disease severity indicators, co-morbidities, 
medications, and CR attendance using a standardized case report form (Appendix C). Resting heart 
rate, blood pressure, body weight, and waist circumference were measured using a BPTru machine 
(calibrated annually by University of Ottawa Heart Institute (UOHI)), a digital scale (calibrated 
annually by University Health Network (UHN)), and a tape measure, respectively.  Participants were 
also asked to complete a self-report survey (Appendix D).  
   All participants were asked to return to the study centers for follow-up assessments at 26 and 
52 weeks after randomization (Appendix E & F). Both the 26 and 52 week follow-up time points 
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coincided with the mid- and end-point of the facilitator intervention. Resting heart rate, blood pressure, 
body weight, and waist circumference were again measured using calibrated instruments. Participants 
were also instructed to bring any medications they were currently taking to be documented.  
Participants were also asked to complete a questionnaire assessing QoL, out-of-pocket expenses (e.g., 
exercise-related products and services, taxi fares, parking fees), and items related to productivity, 
including lost work days, home care expenses due to reduced function or cardiac disability(Appendix 
G & H).  
3.3 SETTING 
 
The trial was conducted at three sites: UOHI in Ottawa, the Peter Munk Cardiac Centre 
(PMCC) and Toronto Rehabilitation Institute (TRI) of the UHN in Toronto. The UOHI and UHN CR 
programs served a mixture of rural and urban patients from large ethnic communities. The length of 
CR programs ranged from 8-24 weeks in duration.   
Participants underwent medical and coronary risk factor assessments during their CR exercise 
sessions 2-3 times each week, and received personalized exercise prescriptions. Participants in Ottawa 
also had the opportunity of attending up to three nutrition workshops. Participants in Toronto had risk 
factor modification discussions during each exercise visit and the opportunity to attend some 
workshops and seminars that included a nutritional aspect. At all sites, services such as psychological 
and depression counselling, stress management, smoking cessation and nutritional counselling were 
available on an as-needed referral basis. At all sites, discharge summaries were provided to primary 
care providers, and other providers upon the request of the participant.   
3.4 PARTICIPANTS 
 
The ECO-PCR trial had a target enrollment of 416 participants (224 men and 192 women) based 
on sample size calculations from pilot work. The inclusion criteria were:  
1. Currently participating in an on-site CR program of ≥ 8-week duration  
2. Patient has graduated from CR  
3.  Has a documented diagnosis of CAD  
4.  18 years of age or older 
5.  Able and willing to provide informed consent 
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6.  Able to walk unaided at 2 miles per hour.  
 
The exclusion criteria were as follows: 
 
1. Has New York Heart Association class III or IV heart failure59  
2. Pregnant, lactating or planning to become pregnant during the study period  
3. Unable to read and understand English or French 
4. Planning to leave the province or region in the next 12 months  
5. Member of the participant’s household is already participating in the study 
6. Unable, in the opinion of the qualified investigator, to participate in unsupervised exercise. 
 
 
3.5 RANDOMIZATION AND BLINDING 
 
Participants were randomized in a 1:1 ratio through the aid of a statistical consultant. 
Participants were stratified by site and gender through sequences that was computer-generated in 
permutated blocks of 4, 8, and 10. The computer-generated sequences were placed in sealed, 
numerically identified opaque envelopes to ensure that treatment allocation was concealed until after 
baseline data collection. Post-baseline data collection, study coordinators were given the next available 
computer-generated sequence; patient randomization sequences were then filed after the participant 
was notified of their allocated group.  
Follow-up assessments for the 26 and 52 week time points were performed by research 
assistants who were blinded to the participant’s treatment allocation. Participants were instructed not  to 
reveal their treatment allocation, and questionnaires were only identifiable through a numeric research 
ID. 
3.6 INTERVENTION 
 
Upon randomization to the exercise facilitator group, participants received a booklet that 
contained information about exercise regimens and routines to be completed during the intervention, a 
pedometer, and an activity workbook that was to be used to record the date, time, location, mode, 
duration and intensity of their physical activities.  Appendix I outlines the exercise facilitator 
intervention format, duration, timing, and the content over the 52-week intervention period.  As shown, 
the intervention consisted of an introductory face-to-face session (this happened two weeks post-
randomization), and consisted of both individual and group teleconferences.   
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The facilitator intervention was based on the socio-ecological model
60
.  This model highlighted 
the importance of individual variability on behaviour in response to the changing social or physical 
environment
61
. The model posits that there are individual (e.g. knowledge, attitudes, and skills), social 
environmental (e.g., friends, family, and social networks) and physical environmental (e.g. home, 
neighbourhood and community characteristics, weather) factors that influence physical activity
62, 63
. 
Each of factors mentioned has both an independent and interdependent effects on PA maintenance.   
Intervention participants were formed into small groups (5-8 participants).  During the 
teleconferences, the importance of exercise maintenance to maintain improvements in cardiometabolic 
fitness from CR was emphasized.  The recommended standard for exercise maintenance in patients 
with CAD was reiterated (i.e., 150 minutes of moderate to vigorous- intensity PA per week
64
). The 
facilitator also helped participants develop plans for adhering to this exercise standard.  Suggestions 
for mapping out walking routes and the use of exercise equipment in the home, community and 
workplace were also discussed.   
Small group counseling teleconferences were held 1, 13, 26, 39 and 50 weeks after 
randomization. During each of the group teleconferences, all participants were encouraged to discuss 
any barriers they had faced to date. With each identified barrier, solutions were brainstormed as a 
group. In addition, the facilitator reviewed their activity diaries and general goals. Approximately, 
every 2-3 weeks for the duration of the intervention period, or as requested by the participant, exercise 
facilitators conducted community program demonstrations at Heart Wise Exercise programs and other 
community exercise facilities in Ottawa and Toronto. There are > 75 and > 25 Heart Wise Exercise 
programs within a 45-minute radius of the Ottawa and Toronto sites, respectively. Participants were 
also informed of the date and time of all demonstrations by e-mail or telephone.   
As per protocol, the facilitator contacted participants 20, 34 and 45 weeks after CR program 
completion for their individual telephone calls. During each call, the facilitator reviewed the 
participant’s interventional journal, previous goals, and finally assessed their confidence and 
motivation with respect to exercise maintenance. Barriers and solutions were discussed as appropriate.  
Attendance records were also kept for all contacts.  
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Facilitators received training prior to initiating any teleconferences with the participant. The 
facilitators also participated in quarterly case discussions (teleconferences between the Ottawa and 
Toronto exercise facilitators) and booster sessions to maintain skills over time. Facilitators were 
required to record their training hours and time spent during in-person community demonstrations and 
teleconferences. To ensure consistent delivery of the intervention at both sites, facilitators recorded a 
random subset of individual and group calls, which were then audited.  
 Participants in the usual care group had access to the activities and strategies available to CR 
graduates at both the UOHI and UHN sites. All participants in their respective sites were provided with 
an updated individualized exercise prescription and exercise maintenance strategies by a program staff 
during CR. The usual care at UHN also had access to an alumni/maintenance program that offer group 
exercise sessions for CR graduates. 
3.7 MEASURES 
 
 Socio-demographic characteristics (i.e., age, gender, ethnic background, living arrangements, 
education, income, employment and marital status) were assessed via self-report (see Appendix D, 
section A). Clinical characteristics (i.e., referral indication, body mass index, hypertension and 
dyslipidemia) were extracted from the CR charts, while smoking history and functional status (Duke 
Activity Status Index
65
) were gathered through self-report.  The purpose of this assessment was to 
describe the study population and assess if there were any differences among the two randomized 
groups (independent variable). 
 To assess societal costs, all participants were requested to complete a monthly diary to record 
time for counselling and physical activities, out-of-pocket expenses (e.g., exercise-related products and 
services, taxi fares, parking fees), and items related to productivity, including  lost work days, home 
care expenses due to reduced function or disability associated with their cardiac conditions. This diary 
aimed to facilitate patient recall in completion of the costing items in the 26 and 52 week surveys (see 
Appendix J).  
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To assess cardiac-related health care resource usage, investigator-generated items on care and 
costs developed based on Oliveira et al.
66
 was administered in both the 26 and 52 week surveys (see 
Appendix G & H, section N). These questions assessed the frequency of cardiac-related emergency 
room visits and hospital admissions in the past 26 weeks. In addition to these visits, the number of 
heart conditions and procedures performed in the last 26 weeks were assessed. Reported usage of 
health care resources was then translated into a monetary value in order to perform a cost-benefit 
analysis. This analysis took into account the differential costs between each health care procedure and / 
or visits. In accordance with a previous Canadian study
67
, costs for cardiac-related emergency visits 
were assigned a unit cost of $224 CAD and for cardiac-related hospital admission $2,248 CAD. The 
mean number of visits was then multiplied by its appropriate visit costs to compute a cost-benefit 
analysis.  
QALYs, a measure that takes into account health-related improvements  over a specified time 
horizon
68
, was derived for all participants based on the Euro-QoL (EQ-5D) questionnaire (see 
Appendix G, section C
69
). The EQ-5D assesses 5 dimensions of health (i.e., mobility, self-care, usual 
activity, pain/discomfort, and anxiety/depression), and respondents were asked to rate the degree of 
severity (i.e., no problem, moderate problem, and extreme problem). Each state got a 5 digit score, 
with 1 representing ‘no problem’ and 3 representing the worst health state. Based on the Canadian 
tariffs by Bansback et al. (2012), a constant (0.111) was subtracted for any dysfunction, with further 
reductions for other poor health states as indicated by the tariffs. The EQ-5D has been documented to 
have good construct validity and satisfactory internal consistency reliability, as documented by 
Cronbach’s alpha co-efficient of 0.73-0.7471,72. 
Health-related QoL weights were derived from participants’ responses to the EQ-5D at 
baseline, 26 and 52 weeks. By using the area-under-the-curve method 
68
 which effectively weights 
time by QoL values, QALYs were calculated for each time point. Upon calculating incremental costs 
and incremental QALYs associated with the intervention, an ICER was calculated.  
To assess the cost-effectiveness of the intervention, data on the resources used for each 
intervention, including training time for facilitators, equipment, and phone used for teleconference 
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counselling and community program demonstrations were collected. Costs were then calculated by 
multiplying the quantities of resources used by their appropriate unit costs. 
3.8 STATISITICAL ANALYSES 
 
All analyses were performed using IBM’s Statistical Package for Social Sciences (SPSS) 
Version 22
73
. Descriptive statistics were performed to describe socio-demographic and clinical 
characteristics of the participants. Recruitment, consent and retention rates were described. The 
equivalence of socio-demographic and clinical characteristics of participants in each group were 
confirmed using chi-square or independent samples t-tests, as applicable. The baseline socio-
demographic and clinical characteristics of those retained at 26 and 52 weeks to those who were lost to 
follow-up were compared using chi-square or analysis of variance (ANOVA), as applicable. A 
significance cut-off of p<0.05 was used. 
To assess the first objective, cardiac-related health care usage was compared by group using 
chi-square analyses and t-tests, as applicable. To assess the second objective, QoL for both groups was 
first plotted. By using the area-under-the-curve method which effectively weights time by QoL values, 
QALYs were calculated over each participant’s period of follow-up.  
To assess the third objective, upon calculation of total costs for the intervention and the 
incremental QALYs gained over the trial, cost-per QALY were compared to a WTP threshold of 
$50,000. Although this is a commonly-used benchmark 
74
, an acceptable range of WTP threshold 
ranges from $20,000 to $100,000 
75
. A comparative analysis was then used to assess the cost-
effectiveness of this intervention compared to usual care. 
4.0 Results  
 
4.1 RESPONDENT CHARACTERISITCS  
 
A study flow diagram is shown in Figure 1. Of the 634 eligible patients, 297 participants were 
randomized (16.7% consent rate). Of these, 291 (98.2%) completed the baseline survey. 
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Table 1 displays participant socio-demographic and clinical characteristics by group at baseline. 
The Duke Activity Status Index score indicates that most patients had high functional capacity. 
Interventional participants had approximately double the amount of joint replacements than controls 
(p=0.06). There were no statistical significant differences in participant characteristics by group 
however.  
Overall, 276 (92.9% retention) participants were retained at 26 weeks and 264 (88.9% retention) 
were retained at the 52 week follow-up. Reasons for loss to follow-up are shown in Figure 1. In terms 
of survey completion, 229 (82.9%) participants completed the 26 week survey and 150 (54.3%) 
completed the 52 week survey.  
As shown in Table 2, participants retained at 26 weeks were less likely to have someone at home 
who required caregiving than those lost to follow-up; this difference was also observed at 52 weeks as 
shown in Table 3. In addition to the above, as shown in Table 3, those retained at 52 weeks were also 
more likely to report that they had other comorbidities and were less likely to live with family than 
those lost to follow-up. No other differences in the sociodemographic and clinical characteristics were 
observed between the retained and non-retained participants. 
Participants were asked to report their occupation at the time of their first cardiac event in the 26 
week survey. Overall, 84 (37.2%) reported being retired, 54 (23.9%) a professional, 30 (13.3%) being 
a manager or administrator, 17 (7.5%) in sales occupations, 7 (3.1%) being in a clerical related career, 
6 (2.7%) not working, 4 (1.8%) being in service occupations, 4 (1.8%) each reported being vehicle or 
equipment operators and laborers, 3 (1.3%) in skilled crafts and 1 (0.4%) in the military. A total of 21 
(7.1%) participants had reported that their heart disease lead them to retirement or disability. 
4.2 HEALTHCARE UTILIZATION AND QALYS  
 
 Cardiac-related healthcare service encounters participants reported in the 26 and 52 week post-
CR surveys (during the preceding six months) are shown in Table 4. With regard to objective 1, 
participants in the facilitator intervention were significantly less likely to report being admitted to the 
hospital and visiting the emergency department at 26 weeks. At 52 weeks however, we observed that 
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the intervention were more likely to be admitted to the hospital than the control group while 
emergency department visits were reported to be similar to findings at 26weeks. No other differences 
were observed at either assessment point. 
 Cardiac events and procedures participants reported in the 26 and 52 week post-CR survey 
(during the preceding six months) are shown in Table 5 by group. “Other” procedures and conditions 
reported by participants included atrial fibrillation and description of symptoms such as sharp pain. 
There were no significant differences by group.  
At 26 and 52 weeks, participants reported paying a mean of $493.24 ± 423.07 and $601.15 ± 
415.66 of their own money to attend these healthcare visits (Table 6), respectively (e.g., transportation, 
parking, food). This did not differ by group (p=0.18 and p=0.43) at either 26 or 52 weeks, respectively. 
Participants in the intervention group reported being accompanied on these healthcare visits by no one 
(n=131, 70.8%), a partner (n=59, 32.1%), sibling (n=2, 1.1%), or a child 2 (1.1%).The person that 
accompanied the participant was most often a female (n=45, 75.0%), aged 63.1 ± 9.6. 
 At 52 weeks, 15 (19.2%) participants reported they had difficulty working due to their heart 
disease, and that they missed 4.4±17.9 days of work since graduating from CR (p=0.44). Four (5.2%) 
participants reported they were unable to do household chores, and 4 (5.2%) reported there were 
unable to participate in their usual leisure activities due to CVD. Throughout the duration of the study, 
a total of 67 (22.6%) of participants bought equipment related to their CVD, such as treadmill and 
running shoes. A total of 2 (1.3%) participants reported using community services for CVD at 52 
weeks. No differences between the time points among the groups were observed (Table 7).    
Overall QoL measured at the 26 week and 52 week follow-up was quite high (Figure 2). QoL 
did not differ significantly by group or by time. To assess effectiveness, QALYs were tracked over the 
52 weeks. The interventional group had gained 0.919 QALYS while those in the usual care had gained 
0.921 QALYs 52 weeks post-CR.  
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4.3 COST- BENEFIT ANALYSIS  
 
 From a health care perspective, the benefits were translated into monetary values as shown in 
Table 8. Decreases in cardiac-related emergency department visits and hospital admissions were 
assigned appropriate costs
67
, and then compared with the cost of the intervention. At 26 weeks, the 
intervention group consumed $43.10 worth of less health care resources; this effect however was 
opposite at 52 weeks. At 52 weeks, since the intervention had more hospital admissions, this resulted 
in the intervention group consuming $144.62 worth of more health care resources. From a societal 
perspective, our conclusion remained the same as there was no significant difference among the direct 
and indirect costs for patients in both groups throughout the 52 weeks (Table 7).   
4.4 COST-UTILITY ANALYSIS  
 
Costs for implementing the intervention for 52 weeks were computed, and are shown in Table 9. 
Facilitator training took 15 hours. Intervention delivery required 5.6 facilitator hours per participant. 
The overall intervention cost as shown in Table 9, was $28,310.13 Canadian dollars (CAD); this 
averaged to $190.00 CAD per patient. From a health care perspective, the usual care was assumed to 
have no cost in comparison to the intervention since the study absorbed any costs for transportation, 
and the usual care had no interaction with the exercise facilitator. Using a theoretical approach, the cost 
of the intervention per patient was divided by the incremental QALYs to result in a cost effectiveness 
ratio of - $95,000.00 CAD per decrease in one QALY (calculation not shown).The difference in 
QALYs however was minute to provide insight into the real cost-effectiveness of the intervention. 
Given a decrease in health care resources at 26 weeks, and some decline at 52 weeks, the intervention 
does have some indicators of being a cost-effective intervention.  
5.0 Discussion  
 
The ECO-PCR trial is the first Canadian study to investigate the economics of an exercise 
facilitator intervention post-CR for reducing health care costs. Cardiac rehabilitation graduates 
randomized to the intervention reported fewer cardiac-related hospital admissions and emergency 
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department visits at 26 weeks. At 52 weeks, only fewer emergency department visits were observed 
than those in the control group, however there were no significant differences in heart-related events or 
procedures. Our hypothesis with respective to objective 1 was thus partially confirmed. Since QoL 
scores had a ceiling effect, the only differences in QALYs between the two groups were 0.002 
QALYs. Given the results from our cost-benefit analysis, our hypothesis that the intervention was cost-
effective was only sustained at 26 weeks.  
Our preliminary finding that exercise facilitation post-CR may reduce healthcare utilization is 
consistent with previous research
76
. A randomized controlled trial by Jannsen et al.
76
 assessed the 
effects of a CR exercise maintenance intervention where group sessions were designed to encourage 
goal-setting, self-reward strategies and generate alternative pathways to goal attainment. The 
intervention was shown to reduce cardiac-related hospital admissions by 20% over a 15 month follow-
up when compared to usual care. These findings were similar to what was observed in our 
interventional group at 26 weeks for both hospital admissions and emergency department visits. At 52 
weeks post-CR however, the intervention group reported higher hospital admissions, suggesting that 
our intervention had an early cost-benefit that was not sustained. This association may be spurious 
however, due to inflated error from multiple comparisons. 
Since our cost-benefit analysis suggested an early interventional benefit that was then 
diminished at 52 weeks, a cost-utility analyses was then used as a hallmark to further robust our 
findings. In general, when a cost-utility value is below the WTP threshold of $50,000, a standard in 
North America
77
, the intervention is deemed cost-effective. Our interventional study resulted in a 
negative cost-utility ratio, suggesting that the intervention may not be cost-effective. The negative 
cost-utility stemmed from the minute differential QALYs between both groups, and one explanation to 
this may be the ceiling effect from the EQ-5D questionnaire.  
The decision of which QoL questionnaire to use has sparked some debate since QoL is closely 
tied with the decision as to whether a trial is cost-effective. One of commonly reported limitations in 
using the EQ-5D questionnaire is its ceiling effect
78
. Some studies suggest that the EQ-5D has been 
shown to successfully discriminate between different health states while other have shown that EQ-5D 
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has been shown to result in higher utility values than EQ-5D
79
. While the EQ-5D questionnaire has 
been successfully administered to a CR population 
80
, it is possible that this questionnaire might not 
have been sensitive enough to detect any differences in QoL gained from our interventional study.  
5.1 IMPLICATIONS AND DIRECTIONS FOR FUTURE RESEARCH 
 
Should the intervention be shown to effectively promote exercise maintenance as well (primary 
outcome of the trial), the implications of these preliminary findings are that offering an exercise 
facilitator intervention for 26 weeks post-CR, may be cost-effective for the health care system. An 
excellent model of broad and standardized provision of post-CR exercise maintenance is the BACPR 
Phase IV model
81
. Phase IV CR is a long-term maintenance program offered in established community 
settings with the aim of shifting the responsibility on the individual to keep physical active
82
.  BACPR 
offers standardized Phase IV exercise instructor training. In Ontario, the Heartwise Exercise program 
(http://heartwise.ottawaheart.ca/) serves as another model to more broadly facilitate exercise 
maintenance post-CR. CR graduates are provided a list of local community programs where the 
facilities meet the 6 principles established for safely exercising. The exercise instructors at these 
settings also receive training (albeit informal) on safe exercise for patients with cardiac disease.  
A ceiling effect was observed with the EQ-5D-3L. This was likely due to the benefits of CR 
participation, particularly as patients who were highly adherent to the program were selected for 
inclusion in this trial.  In future studies, administration of direct QoL questionnaires should be 
considered, such as the time trade-off scale
83,84
.  
At the end of this trial, the data will be linked to the health administrative data housed at the 
Institute for Clinical Evaluative Sciences to ascertain health care utilization. Health effects will be 
measured in terms event-free time from a cardiac event or revascularization procedure, and then 
translated into overall QALYs. The analysis will take the societal perspective, with a time horizon of 
78 weeks.  Upon obtaining data for emergency department visits, hospitalizations, day procedures, 
general and specialist visits, a more comprehensive cost-effectiveness analysis of the intervention will 
be performed by using CAD associated Canadian resource intensity weights.   
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5.2 LIMITATIONS 
 
Caution is warranted in interpreting our results. First, since the primary objective of this study 
was to assess PA levels with the facilitator intervention, one of the biggest limitations was that the trial 
was not powered to test differences in the outcomes tested herein. Healthcare use is a relatively rare 
event, and hence lack of associations may merely be a function of the sample size, not a true lack of 
association. Second, results regarding whether the intervention successfully increased PA levels post-
CR are not yet available, as the trial is ongoing. This limits capacity to interpret the effects observed 
herein. Third, despite administering a QoL questionnaire, it seems as this questionnaire might not be 
sufficient to fully understand and assess the intervention benefits in a population with already high 
QoL. Fourth, generalizability is limited to patients who gain access to CR programs and complete 
them. Fifth, given majority of the data was collected through self-reported measures from follow-up 
surveys, this invited the possibility of having social desirability bias. Sixth, despite providing 
participants costing diaries to record expenses through the 52 weeks of the study, these diaries were 
not widely used, such that inaccurate recall may have resulted. Finally, the health care cost items were 
investigator-generated, and despite the fact that they were previously administered in oncology 
patients
85
, the validity and reliability of the items in cardiac patients is unknown.  
6.0 Conclusion 
 
In conclusion, cardiac patients receiving exercise facilitation for 52 weeks following CR 
reported lower usage of costly health care services due to their cardiac condition at the 26 and 52 week 
follow-up compared to control patients; one exception to this observed effect was that the intervention 
group had reported more hospital admissions than the control at 52 weeks. Patients in both groups had 
a high QoL throughout the course of the study, and this did not differ by group. The cost-benefit 
analysis suggests that the intervention appears to be promising from a societal perspective. This study 
provides insight into potential savings, particularly related to reductions in costly emergency 
department visits with patient use of outpatient visits instead, even though a comprehensive cost-utility 
analysis was not possible due to a ceiling effect in QoL. Ongoing research is needed to assess the 
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association between an exercise facilitator intervention and QoL, to better assess cost-utility. In 
conjunction with planned future analyses using administrative data and pending determination of 
intervention effectiveness for exercise maintenance, our results could be used to inform policy-makers 
regarding the economic benefits of delivering exercise facilitation for patients post-CR.  
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Figure 1: ECO-PCR Study Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n= 1782) 
Excluded (n= 1485) 
   Declined to participate/other (n=534) 
  No CAD diagnosis (n=394) 
   Did not complete CR program (n=239) 
 Unable to walk 2mph  (n=167) 
 Does not read English or French (n=61) 
 Leaving province in the next 12 months (n=54) 
   Participating in a CR program <8 weeks (n=21) 
 Has class III or IV heart failure (n=9) 
 Unable to provide informed consent (n=5) 
 <18 years of age (n=1) 
 
Analysed (n=127)  
 
Lost to follow-up (n=22) 
 Patient unreachable (n=14) 
 No longer interested in study (n=7 ) 
 Moved to unknown address (n=1) 
 
Intervention (n=149) 
Lost to follow-up (n=20) 
 Patient unreachable (n=12) 
 Number not in service (n=5) 
 No longer interested in study (n=2 ) 
 Moved to unknown address (n=1) 
 
Usual care (n=148) 
Analysed (n=128)  
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Figure 2: Quality of Life (QoL) score by group over time   
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* p>0.05 for change in QoL scores for both groups throughout the duration of the study, 
and for differences by groups at each time point. Quality adjusted life years (QALYs) were 
computed by finding the area under each graph. 
29 
 
Table 1: Participant sociodemographic and clinical characteristics post-CR by group 
  
 
 
 
 
 
 
 
 
 
 
Characteristics Usual Care 
n= 148 (49.8%) 
Intervention Group 
n= 149 (50.2%) 
p Total 
N=297 
Sociodemographic     
Age (mean ± SD) 63.1 ± 9.7 63.7 ± 9.6 0.87 63.4 ± 9.7 
Sex (% Male) 111 (75.0%) 113 (76.3%) 0.45 224 (75.7%) 
Racial/Ethnic Background (% White/Caucasian) 117 (85.4%) 120 (91.6%) 0.15 237 (88.4%) 
Living Arrangements (% with Family) 101 (73.7%) 100 (75.8%) 0.54 201 (74.7%) 
Living with Someone Who Requires Caregiving 10 (7.4%) 10 (7.6%) 0.56 20 (7.5%) 
Employment Status (% Retired) 64 (46.7%) 66 (50.0%) 0.88 130 (48.3%) 
Marital Status ( % Married/Equivalent) 97 (73.7%) 97 (74.6%) 0.96 198 (74.2%) 
Highest Education (% University or greater) 72 (52.6%) 59 (45.0%) 0.49 131 (48.9%) 
Annual Income ( <$50,000 CAD/year) 59 (46.1%) 58 (47.2%) 0.35 117 (46.7%) 
Referral Indication      
     PCI 91 (61.5%) 98 (66.2%) 0.23 189 (63.9%) 
      MI 75 (51.0%) 74 (50.0%) 0.48 149 (50.5%) 
     CABG Surgery 34 (23.1%) 42 (28.4%) 0.19 76 (25.8%) 
Risk Factors (% yes)     
     Family history of heart disease 99 (73.3%) 104 (79.4%) 0.16 203 (76.3%) 
     Dyslipidemia  70 (47.6%) 60 (40.5%) 0.13 130 (41.0%) 
     Hypertension  57 (38.8%) 64 (38.8%) 0.46 121 (41.0%) 
     History of physical activity  52 (38.2%) 43(32.8%) 0.21 95 (35.6%) 
     Smoking (% current) 3 (2.2%) 1 (0.8 %) 0.38 4 (1.7 %) 
     Body Mass Index (Mean ± SD) 28.4 ± 4.8 28.1 ± 4.8 0.84 28.3 ± 4.8 
Comorbidities     
     Other 90 (60.8%) 86 (58.1%) 0.15 176 (59.5%) 
     Cancer 17 (11.5%) 19 (12.8%) 0.43 36 (12.2%) 
     Joint Replacement 10 (6.7%) 19 (12.8%) 0.06 29 (9.8%) 
     Depression 17 (11.5%) 11 (7.4%) 0.16 28 (9.5%) 
Cardiac Medications     
     ASA 140 (94.6%) 138 (93.2%) 0.40 278 (93.9%) 
     Statins 133 (89.9%) 138 (93.2%) 0.20 271 (91.6%) 
    Other 127 (85.8%) 129 (87.8%) 0.37 256 (86.8%) 
     Beta Blocker 120 (81.1%) 111 (75.0%) 0.13 231 (78.0%) 
     ACE Inhibitors 90 (60.1%) 85 (57.4%) 0.32 175 (59.0%) 
     Nitrates (not PRN) 62 (41.9%) 63 (42.6%) 0.50 125 (42.2%) 
     Clopidrogel/Ticlopidine 56 (37.8%) 68 (45.9%) 0.10 124 (41.9%) 
     Calcium Antagonists 24 (16.2%) 20 (13.5%) 0.31 44 (14.9%) 
     Anti-depressants 20 (13.5%) 19 (12.8%) 0.50 39 (13.2%) 
    Oral hypoglycemic 16 (10.8%) 16 (10.8%) 0.57 32 (10.8%) 
     Diuretics 15 (10.1%) 15 (10.1%) 0.58 30 (10.1%) 
     Anti-Platelets 18 (12.1%) 11 (7.4%) 0.12 29 (9.8%) 
     ARBs 11 (7.4%) 14 (9.5%) 0.34 25(8.4%) 
    Coumadin 9 (6.1%) 8 (5.4%) 0.50 17 (5.7%) 
     Nicotine Replacement 7 (4.7%) 3 (2.0%) 0.17 10 (3.4%) 
    Insulin 3 (2.0%) 6 (4.0%) 0.25 9 (3.0%) 
     Anti-Coagulants 3 (2.0%) 4 (2.7%) 0.50 7 (2.4%) 
     Anti-Arrhythmias 2 (1.4%) 2 (1.4%) 0.70 4 (1.4%) 
    HRT 3 (2.0%) 1 (0.7%) 0.31 4 (1.4%) 
Peak VO2† (ml.kg-1.min-1) 25.1±7.3 24.9±6.5 0.12 25.0±6.9 
Resting heart rate (bpm) 64.7±10.9 66.3±11.2 0.71 65.5±11.1 
Systolic blood pressure (mmHg) 120.2±18.2 127.8±82.6 0.35 124.0±60.0 
Diastolic blood pressure (mmHg) 71.8±9.3 72.9±9.9 0.30 72.4±9.6 
Duke Activity Status Index (Mean ± SD) 46.7±12.7 47.1±11.1 0.17 46.3±11.8 
CR= Cardiac Rehabilitation; CAD= Canadian Currency; PCI- Percutaneous Coronary Intervention; MI- Myocardial Infarction; CABG- 
Coronary Artery Bypass Graft; PVD- Peripheral Vascular Disease; SD- Standard Deviation; PRN- “when necessary”; BPM- beats per minute 
†275 available in random sub-sample of 297 participants. 
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Table 2: Post-CR (baseline) sociodemographic and clinical characteristics by 
retention at 26 week follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Retained† 
n= 276 (92.9%) 
Lost to follow-up 
n= 21(7.1%) 
p 
Sociodemographic    
Age (mean ± SD) 63.5 ± 9.8 63.0 ± 8.6 0.35 
Sex (% Male) 207 (75.3%) 17 (80.9%) 0.39 
Racial/Ethnic Background (% White/Caucasian) 225 (88.9%) 12 (80.0%) 0.10 
Living Arrangements (% with Family) 186 (73.2%) 15 (71.4%) 0.07 
Living with Someone Who Requires Caregiving 15 (5.9%) 5 (33.3%) <0.01 
Employment Status (% Retired) 122 (48.0%) 8 (53.3%) 0.57 
Marital Status ( % Married/Equivalent) 184 (74.2%) 14 (93.3%) 0.26 
Highest Education (% University or greater) 124 (49.0%) 7 (46.7%) 0.61 
Annual Income ( <$50,000 CAD/year) 110 (46.4%) 7 (50.0%) 0.83 
Referral Indication     
     PCI 177 (64.4%) 12 (57.1%) 0.33 
     MI 140 (51.1%) 9 (42.9%) 0.31 
     CABG surgery 71 (25.9%) 5 (23.8%) 0.53 
Risk Factors (% yes)    
     Family history of heart disease 192 (76.5%) 11 (73.3 %) 0.49 
     Hypertension  114 (41.6%) 7 (33.3 %) 0.72 
     Dyslipidemia  123 (44.9%) 7 (33.3%) 0.21 
     History of physical activity  90 (35.7%) 5(33.3%) 0.55 
     Smoking (% current) 4 (1.6%) 0 (0%) 0.89 
     Body Mass Index (Mean ± SD) 28.4 ± 4.8 28.1 ± 4.8  
Comorbidities    
     Other 167 (60.7%) 9 (42.9%) 0.36 
     Cancer 33 (12.0%) 3 (14.2%) 0.48 
     Joint Replacement 26 (9.5%) 3 (14.2%) 0.34 
     Depression 26 (9.4%) 2 (9.5%) 0.61 
Cardiac Medications    
     ASA 260 (94.5%) 18 (85.7%) 0.13 
     Statins 253 (92%) 18 (85.7%) 0.26 
     Beta Blocker 213 (77.4%) 18 (85.7%) 0.28 
    Other 238 (86.9%) 18 (85.7%) 0.50 
     ACE Inhibitors 161 (58.5%) 14 (66.7%) 0.31 
     Nitrates (not PRN) 116 (42.2%) 9 (42.9%) 0.56 
     Clopidrogel/Ticlopidine 118 (42.9%) 6 (28.6%) 0.15 
     Diuretics 26 (9.4%) 4 (19.0%) 0.15 
    Oral hypoglycemic 28 (10.2%) 4 (19.0%) 0.18 
     Anti-depressants 36 (13.1%) 3 (14.3%) 0.54 
     Anti-Coagulants 5 (1.8%) 2 (9.5%) 0.08 
     Calcium Antagonists 42 (15.3%) 2 (9.5%) 0.37 
     Anti-Platelets 28 (10.2%) 1 (4.8%) 0.37 
     Anti-Arrhythmias 3 (1.1%) 1 (4.8%) 0.26 
     ARBs 24 (8.7%) 1 (4.8%) 0.45 
    Coumadin 16 (5.8%) 1 (4.8%) 0.66 
    Insulin 8 (2.9%) 1 (4.8%) 0.49 
     Nicotine Replacement 10 (3.6%) 0 (0%) 0.47 
    HRT 4 (1.5%) 0 (0%) 0.74 
Peak VO2† (ml.kg-1.min-1) 25.1±7.0 23.2±4.0 0.06 
Resting heart rate (bpm) 65.2±11.1 68.5±11.0 0.94 
Systolic blood pressure (mmHg) 124.5±62.1 118.4±12.7 0.54 
Diastolic blood pressure (mmHg) 72.4±9.6 72.1±9.4 0.84 
Duke Activity Status Index (Mean ± SD) 46.2±12.4 47.1±10.2 0.68 
CR= Cardiac Rehab; CAD= Canadian Currency; PCI- Percutaneous Coronary Intervention; MI- Myocardial Infarction; CABG- Coronary 
Artery Bypass Graft; PVD- Peripheral Vascular Disease; SD- Standard Deviation; PRN- “when necessary”; BPM- beats per minute 
*p<.05 
†276 available in random sub-sample of 297 participants. 
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Table 3: Post-CR socio-demographic and clinical characteristics by retention at 52 
week follow-up  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics Retained 
n= 264 (88.9%) 
Lost to follow-up 
 n= 33 (11.1%) 
p 
Sociodemographic    
Age (mean ± SD) 63.7 ± 9.8  61.5 ± 8.8  0.68 
Sex (% Male)  196 (74.5%) 28 (84.8%) 0.14 
Racial/Ethnic Background (% White/Caucasian) 214 (88.4%) 23 (88.5%) 0.53 
Living Arrangements (% with Family) 176 (72.4%) 25 (96.1%) 0.02 
Living with Someone Who Requires Caregiving 13 (5.4%) 7 (26.9%) <0.001 
Employment Status (% Retired) 117 (48.1%) 13 (50.0%) 0.87 
Marital Status ( % Married/Equivalent) 174 (72.2%) 24 (92.3%) 0.14 
Highest Education (% University or greater) 121 (50.0%) 10 (38.5%) 0.08 
Annual Income ( <$50,000 CAD/year)  105 (46.1%) 7 (50.0%) 0.84 
Referral Indication     
     PCI  172 (65.4%) 17 (51.5%) 0.09 
     MI  136 (51.9%) 13 (39.4%) 0.12 
     CABG surgery  67 (25.5%) 9 (28.1%) 0.45 
Risk Factors (% yes)    
     Family history of heart disease  183 (76.3%) 20 (76.9%) 0.58 
     Dyslipidemia   118 (45.0%) 12 (36.4%) 0.23 
     Hypertension  111 (42.4%) 10 (30.3%) 0.38 
     History of physical activity  87 (36.1%) 8 (30.8%) 0.38 
     Smoking (% current)  4 (1.7%) 0 (0 %) 0.80 
     Body Mass Index (Mean ± SD) 28.2 ± 4.8 28.7 ± 4.9 0.80 
Comorbidities    
     Other 163 (62.2%) 13 (39.4%) <0.05 
     Cancer  30 (11.4%) 6 (18.2%) 0.20 
     Joint Replacement 26 (9.9 %) 3 (9.0%) 0.59 
     Depression 26 (9.9%) 2 (6.1%) 0.37 
Cardiac Medications    
     ASA  248 (94.3%)  30 (90.9%) 0.32 
     Statins  241 (91.6%)  30 (90.9%) 0.55 
     Beta Blocker  202 (76.8%)  29 (87.8%) 0.11 
    Other 230 (87.8%) 26 (78.8%) 0.12 
     ACE Inhibitors 156 (59.3%)  19 (57.6%) 0.50 
     Nitrates (not PRN)  112 (42.6%)  13 (39.4%) 0.44 
     Clopidrogel/Ticlopidine  114 (43.3%)  10 (30.3%) 0.11 
    Oral hypoglycemic 26 (9.9%) 6 (18.2%) 0.13 
     Diuretics  25 (95.1%)  5 (15.2%) 0.23 
     Calcium Antagonists  40 (15.2%)  4 (12.1%) 0.43 
     Anti-depressants  36 (13.7%)  3 (9.0%) 0.34 
    Coumadin  15 (5.7%) 2 (6.0%) 0.59 
    Insulin 7 (2.7%) 2 (6.0%) 0.26 
     Anti-Coagulants 5 (1.9%)  2 (6.1%) 0.18 
     Nicotine Replacement  9 (3.4%)  1 (3.0%) 0.70 
     Anti-Arrhythmias  3 (1.1%)  1 (3.0%) 0.38 
     ARBs 24 (9.1%)  1 (3.0%) 0.20 
     Anti-Platelets 28 (10.6%)  1 (3.3%) 0.14 
    HRT 4 (1.5%) 0 (0%) 0.62 
Peak VO2† (ml.kg-1.min-1) 25.0±7.0 24.6±4.7 0.10 
Resting heart rate (bpm) 65.3 ± 11.2 67.3 ± 10.4 0.75 
Systolic blood pressure (mmHg) 125.0±63.4 116.6±15.1 0.55 
Diastolic blood pressure (mmHg) 72.6±9.6 67.3±10.4 0.75 
Duke Activity Status Index (Mean ± SD) 46.9±11.3 48.0±10.3 0.78 
CR= Cardiac Rehab; CAD= Canadian Currency; PCI- Percutaneous Coronary Intervention; MI- Myocardial Infarction; CABG- Coronary Artery 
Bypass Graft; PVD- Peripheral Vascular Disease; SD- Standard Deviation; PRN- “when necessary”; BPM- beats per minute 
†264 available in random sub-sample of 297 participants. 
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Table 4: Cardiac-related health care resource use (mean number of visits ± 
standard deviation) by group 
 
 Usual Care 
n=148 (49.8%) 
Intervention  
n=149 (50.2%) 
p Total 
N=297 
26 weeks post-CR     
Family Physician 2.53 ± 2.04 
(n=104) 
2.82 ± 3.00 
(n=100) 
     0.09 2.67 ± 2.50 
Cardiac Specialist 1.33 ± 1.19 
(n=89) 
1.27 ± 1.24 
(n=81) 
 
0.70 1.30 ± 1.21 
Emergency Department 0.33 ± 0.71 
(n=27) 
0.22 ± 0.51 
(n=18) 
<0.01* 0.27 ± 0.62 
Admitted to Hospital 0.16 ± 0.39 
(n=17) 
0.07 ± 0.28 
(n=6) 
<0.01* 0.11 ± 0.35 
52 weeks post-CR     
Seen your family doctor 2.41 ± 2.0 
(n=70) 
2.36 ± 3.2 
(n=62) 
0.67 2.39 ± 2.7 
Seen a heart specialist 1.04 ± 0.81 
(n=59) 
0.88 ± 0.90 
(n=44) 
 
0.44 0.97 ± 0.85 
Went to emergency department 0.26 ± 0.52 
(n=17) 
0.14 ± 0.43 
(n=8) 
<0.01* 0.20 ± 0.48 
Been admitted to the hospital 0.05 ± 0.22 
(n=4) 
0.19 ± 0.99 
(n=13) 
0.02* 0.12 ± 0.70 
 
CR= Cardiac Rehabilitation;  
*p<.05 between usual and intervention group 
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Table 5: Procedures and heart conditions by group 
 
 Usual Care 
n=148 (49.8%) 
Intervention  
n=149 (50.2%) 
p Total 
N=297 
26 weeks Post-CR     
Other 13 (11.7%) 14 (12.7%) 0.49 27 (12.2%) 
Angina 13 (11.7%) 12 (10.9%) 0.51 25 (11.3%) 
Percutaneous Coronary Intervention 5 (4.5%) 3 (2.7%) 0.37 8 (3.6%) 
None of the Above 86 (76.1%) 77 (70.0%) 0.19 163 (73.1%) 
     
52 weeks Post-CR     
Angina 5 (6.5%) 8 (11.6%) 0.22 13 (9.0%) 
Other 4 (5.3%) 2 (2.9%) 0.39 6 (4.1%) 
None of the above 65 (87.8%) 55 (84.6%) 0.38 120 (86.3%) 
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Table 6: Out-of-pocket patient costs for medications and health care visits by group 
 
 
 
Medication Costs 
Post-CR Control Intervention p 
26 weeks $ 580.33 ± 559.37 $ 584.15 ± 623.43 0.74 
52 weeks $ 448.02 ± 469.09 $ 549.54 ± 446.56 0.78 
Health Care Visit Costs 
Post-CR Control Intervention p 
26 weeks $ 570.68 ± 405.02 $ 493.24 ± 423.07 0.18 
52 weeks $ 544.23 ± 388.63 $ 601.15 ± 415.66 0.43 
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Table 7: Societal costs by group at 52 weeks 
 
  
N (%)   
Intervention Usual Care p 
Did you buy any items for a 
problem related to heart disease? 
(equipment, aids, devices) 15 (19.2%) 9 (12.5%) 0.18 
Difficulty working at your paid 
employment due to treatment or 
problems to heart disease? 3 (2.8%) 2 (4.2%) 0.44 
Unable to do chores around the 
house (housecleaning, running 
errands)  due to heart disease 4 (5.2%) 4 (5.2%) 0.58 
Unable to participate in leisure 
activities due to heart disease? 4 (5.2%) 5 (6.9%) 0.44 
Did you use any community 
services in the last 6 months due 
to heart disease? 1 (1.4%) 1 (1.3%) 0.73 
Have you ever seen a health 
professional or seek treatment for 
heart disease outside Ontario? 5 (6.4%) 2 (2.8%) 0.26 
  
 
mean  ± standard deviation  
Intervention Usual Care p 
How many days of work did you 
miss since you graduated from 
cardiac rehabilitation? 4.4 ± 17.9 5.8 ±13.9 0.44 
In you are not currently working, 
how many days were you unable 
to perform your usual activities? 5.7 ± 24.4 6.3 ± 19.4 0.9 
36 
 
Table 8: Translating intervention benefits into monetary values 
 
 Usual Care Intervention 
 N=114 N=115 N=79 N=71 
Time Post-CR 26 weeks 52 weeks 26 weeks 52 weeks 
Hospital admissions  $361.28 $112.90 $429.02 $270.94 
ER Visits  $73.92 $58.24 $49.28 $44.80 
     
Total  $435.20 $171.14 $478.30 $315.76 
 
 
Note: amounts shown in Canadian dollars. 
CR=Cardiac Rehabilitation 
* costs based on Rinfret et al.
67
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Table 9: Micro-costing from health care perspective for the intervention group 
 
Item Unit Price  Total Cost  
Training Exercise Facilitator 
(Includes training and 
patient call times) 
$25.41 $21,318.99 
Teleconference Calls $220.47 $2645.64 
Pedometer Costs $13.00 $1755.00 
Workbook Costs $23.55 $2590.50 
 
Note: amounts shown in Canadian dollars. 
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8.0 APPENDICES 
APPENDIX A: Trial Diagram 
 
 
 
Participants (224 men, 
192 women) providing 
informed consent and 
completing baseline 
assessment (physical 
activity, cardiometabolic 
indicators, QoL, and 
ecological influences. A 
random sample will 
complete a stress test at 
baseline. 
Exclude patients: 
Attendance < 75% 
< 18 years of age 
Living > 60 min travel 
time from centre 
With NYHA Class III or 
IV heart failure 
Unable to speak and 
read English or French 
Pregnant or lactating 
Planning to leave the 
province or region in 
the next 12 months 
Unable to walk unaided 
at 2mph 
Patients with CAD 
completing on-site 
supervised CR 
program ≥ 8 weeks 
at UOHI or UHN 
assessed for 
eligibility 
Usual care group 
(N = 208) 
Brochure for community  Heart 
Wise Exercise programs 
Intervention group (N = 208) 
Introduction session in 
person (1) 
Small group counseling 
teleconferences (5) 
Personal telephone calls (3) 
Community Program 
demonstrations (as needed) 
Follow-up 
Re-assessment of physical 
activity, cardiometabolic 
indicators, QoL and 
ecological influences at 26, 
and 52 weeks 
GXT at 52 weeks  
Follow-up 
Re-assessment of physical 
activity, cardiometabolic 
indicators, QoL and ecological 
influences at 26, and 52 weeks 
GXT at 52 weeks 
Stratification by 
gender and site  
Random assignment 
CAD- Coronary Artery Disease 
UOHI – University of Ottawa Heart Institute  
UHN-University Health Network 
QoL-Quality of Life 
GXT-Graded stress test 
NYHA-New York Heart Association 
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APPENDIX B: CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
 
Study Title: Ecologically Optimizing Exercise Maintenance in Men and Women 
Following Cardiac Rehabilitation: A Randomized Controlled Trial 
of Efficacy with Economics  
 
Sponsor   Heart and Stroke Foundation of Ontario 
 
 
Introduction 
 
You are being asked to take part in a research study. Please read this explanation about the study and 
its risks and benefits before you decide if you would like to take part. You should take as much time as 
you need to make your decision. You should ask the study doctor or study staff to explain anything 
that you do not understand and make sure that all of your questions have been answered before signing 
this consent form. Before you make your decision, feel free to talk about this study with anyone you 
wish. Participation in this study is voluntary. 
 
 
 
Background and Purpose 
 
Physical activity is an important contributor to fitness for patients with heart disease. Canadian 
guidelines recommend 30-60 minutes of moderate to vigorous physical activity most, preferably, all 
days of the week.  
 
Participation in an outpatient cardiac rehabilitation program is the usual first step toward developing an 
exercising lifestyle after a heart problem is diagnosed. About 70-85% of people report achieving 
recommended guidelines for physical activity during the time they are participating in cardiac rehab. 
Unfortunately, these levels of physical activity are often not maintained after participation in the 
program ends.  
 
You have been asked to take part in this research study because you have completed at least 75% of a 
supervised cardiac rehabilitation program at the University Health Network. 
 
We have developed a new intervention to promote the continuation of exercise following cardiac 
rehab. It incorporates an exercise “facilitator” to transition patients from structured, supervised 
exercise to home walking or approved community-based exercise programs (also known as Heart Wise 
Exercise Programs).  
 
This research study will examine whether the facilitator intervention is related to more exercise 
maintenance over the year following cardiac rehab, which elements of the process affected your 
exercise, your clinical profile, and the cost of in the intervention, including whether patients are less 
likely to use the healthcare system. 
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About 416 people from Ottawa and Toronto will be in the study. About 139 people will come from the 
University Health Network (Toronto Western Hospital and the Toronto Rehabilitation Institute cardiac 
rehab programs). 
 
Study Design  
 
This study is a one and a half year study that that will compare an intervention group (exercise 
facilitator) with a control group (usual care). Whether you assigned to the intervention or the control 
group will be decided randomly (by chance) like flipping a coin or rolling dice. The number of people 
getting study intervention will be 208 and the number of people in the control group will be 208. 
 
Study Procedures  
 
Questionnaires 
 
You will be asked to complete four (4) survey questionnaires: one at the beginning of the study, one at 
26 weeks (6 months), one at 52 weeks (1 year) and one at 78 week (1.5year). The questionnaires will 
ask you about your demographics (age, gender, education), lifestyle (exercise behaviours, cardiac risk 
factors, medications), as well as questions about your health and emotional well-being. Completion of 
the questionnaires will require approximately 45 minutes of your time. 
 
Intervention Group  
 
Participants in the intervention group will receive five small group counselling teleconferences, be 
invited to multiple community exercise program demonstrations, and three personal telephone calls 
from a trained exercise facilitator over a 50-week (almost 1 year) intervention period.  
 Small group teleconferences will take place in study weeks: 3, 13, 26, 39 and 50. These 
sessions are 60 minutes long. 
 Personal (individual phone calls) will take place in study weeks: 20, 34 and 45. These sessions 
are 15-30 minutes long. 
 A random sub-sample of these calls would be audio taped with your permission so we can audit 
the consistency of the session content the facilitator is providing. 
 The above activities will actively explore and review your exercise behaviours and barriers.  
 
Usual Care Group  
 
The usual care group will receive the usual exercise advice provided to patients exiting cardiac 
rehabilitation at the study centers. Patients in both programs are provided with an updated exercise 
prescription and a home-based walking program prior to program completion and exercise 
maintenance strategies are reviewed with program exercise staff. There is no further patient contact 
after program completion at either program.  
 
Follow-up 
 
Participants in both groups will have their follow-up continue through to 78 weeks (1.5 years later). 
 Results from your exit assessments will be collected from your cardiac rehab charts. 
 Measures will be taken at 26 weeks (6 months), 52 weeks (1 year) and 78 weeks (1.5 years) 
after randomization.  
 You will be asked to come on site for these assessments, and complete a survey measuring 
your thoughts and feelings about exercise. It will take approximately 45 minutes to 
complete.  
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 In order to measure your health, we would also like to test your blood pressure and measure 
your waist.  
 You will be asked wear an accelerometer device to measure your physical activity for 9 
days. You will be provided with a pre-paid addressed envelope to return the accelerometer. 
 A randomly-chosen subsample of patients will be asked to do a physician-supervised, 
symptom-limited cardiopulmonary test at the 1-year final assessment only. Cardiac rehab 
graduates from the Toronto Rehabilitation Institute program are asked to do this as a standard 
part of the program, so if this information is available we would simply want to get the results.  
 
As part of the study, we will review your medical records to obtain information about your diagnosis 
and your medical history, including the nature of your cardiac problem, heart history and medications. 
We will also collect the information obtained as part of your rehab program, which includes test 
results, blood pressure and waist measurements, cholesterol levels, as well as your participation level 
and dates of attendance.  
 
Economic Measures 
 
Finally, we would also like permission to link your information gathered from this program with a 
provincial database to determine your health care use and health outcomes over time. This would not 
require any paperwork on your behalf.   
 
Reminders 
 
While you are in this study you should continue with everything your family doctor or cardiac 
specialist has recommended. You will still receive your usual care from your family doctor and cardiac 
specialist. You do not have to stop or change anything. 
 
Potential Risks and Benefits  
 
It is very unlikely that participation in this research study will result in any side effects. The 
Cardiopulmonary stress test will require you to walk (starting at a low level with the speed and grade 
slowly increasing throughout the test) on a treadmill with electrodes on your chest in order to see how 
the heart works during exercise. It will help us measure your heart minimal and maximal exercise 
capacity. This test is based on your own efforts and you can stop at any time throughout the procedure. 
There will be a full medical staff supervising the stress test.  
 
 You will be revealing personal information about yourself; however this information will remain 
private.  
 
Benefits to Being in the Study 
 
You may receive direct benefit from being in this study by receiving further support to maintain 
exercise. Your participation will also help us improve the care of future cardiac patients following 
cardiac rehab participation.  
 
Voluntary Participation 
 
Your participation in this study is voluntary. You may decide not to be in this study, or to be in the 
study now, and then change your mind later. You may leave the study at any time without affecting 
your care. You may refuse to answer any question you do not want to answer.  
 
We will give you new information that is learned during the study that might affect your decision to 
stay in the study.   
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Confidentiality 
 
If you agree to join this study, the study doctor and his/her study team will look at your personal health 
information and collect only the information they need for the study.  Personal health information is 
any information that could be used to identify you and includes your: 
 name 
 address 
 email address 
 OHIP number 
 new or existing medical records (including types, dates and results of medical tests or 
procedures) 
 
The information that is collected for the study will be kept in a locked and secure area by the study 
doctor for 10 years.  Only the study team or the people or groups listed below will be allowed to look 
at your records.  Your participation in this study also may be recorded in your medical record at this 
hospital.   
 
 
 
The following people may come to the hospital to look at the study records and at your personal health 
information to check that the information collected for the study is correct and to make sure the study 
followed proper laws and guidelines: 
 Representatives of the study organizing committee.   
 University Health Network Research Ethics Board.   
 
All information collected during this study, including your personal health information, will be kept 
confidential and will not be shared with anyone outside the study unless required by law.  Any 
information about you that is sent out of the hospital will have a code and will not show your name or 
address, or any information that directly identifies you.  You will not be named in any reports, 
publications, or presentations that may come from this study.   
 
If you decide to leave the study, the information about you that was collected before you left the study 
will still be used.  No new information will be collected without your permission.  
 
In Case You Are Harmed in the Study 
 
If you become ill, injured or harmed as a result of taking part in this study, you will receive care. The 
reasonable costs of such care will be covered for any injury, illness or harm that is directly a result of 
being in this study. In no way does signing this consent form waive your legal rights nor does it relieve 
the investigators, sponsors or involved institutions from their legal and professional responsibilities. 
You do not give up any of your legal rights by signing this consent form.  
 
Expenses Associated with Participating in the Study  
 
You will not have to pay for any of the procedures (i.e. stress test) involved with this study. You will 
be reimbursed for your parking costs for your 4 on-site visits to complete study assessments (initial, 
26, 52 and 78 weeks). You will not be paid for participation in this study. 
 
Questions About the Study 
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If you have any questions, concerns or would like to speak to the study team for any reason, please 
call: _________ or the Study Coordinator at _________.  
 
If you have any questions about your rights as a research participant or have concerns about this study, 
call the Chair of the University Health Network Research Ethics Board (REB) at _________or please 
call the Toronto Rehab Research Ethics Board Office at _________.The REB is a group of people who 
oversee the ethical conduct of research studies. These people are not part of the study team. Everything 
that you discuss will be kept confidential.  
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Consent  
 
This study has been explained to me and any questions I had have been answered. I know that I may 
leave the study at any time. I agree to take part in this study.  
 
 
           
Print Study Participant’s Name  Signature   Date  
 
(You will be given a signed copy of this consent form) 
 
My signature means that I have explained the study to the participant named above. I have answered 
all questions.  
 
 
           
Print Name of Person    Signature   Date  
Obtaining Consent 
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Date assessed: _________________ (dd/mm/yy) 
 
 
 
Current Medications 
(check all that apply) 
Medication Name Dose 
 4) ACE Inhibitors 
 
  
 5) Anti-coagulants 
 
  
 6) ASA 
 
  
 7) Ca2+ antagonists 
 
  
 8) Statin 
 
  
 9) LL – fibrate 
 
  
 10) LL – nicotinic acid 
 
  
 11) LL – resin drugs 
 
  
 12) Diuretics 
 
  
 13) Clopidogrel or 
ticlopidine 
  
 
 
Basic Measures 
 
 
1) Weight(kg): __________________ 
 
2) Waist circumference (cm): _______ 
 
3) BP: syst:______/ diast:_______  Heart Rate: _________ 
 
 
 
ECO-PCR CASE REPORT FORM:  26 WEEK FOLLOW UP 
APPENDIX C: Case Report Form (CRF) 
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DATE COMPLETED:(dd/mm/yyyy)_____________________            Participant #___________ 
 
 
 
 
 
 
 
APPENDIX D: ECO-PCR Study 
Initial Survey 
 
 
 
 
Instructions for completing the survey questions appear at the beginning of 
each section. 
 
Please seal your completed questionnaire in the envelope provided, and 
return it to the study coordinator. 
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Instructions: The information within this section is needed to help understand the characteristics of the people 
participating in this study. For this reason, it is very important information. Be assured that it will remain 
confidential. 
 
1. What do you consider to be your racial/ethnic background? Please check   one (1) of the following 
boxes: 
 
 Aboriginal (includes Inuit, Métis peoples of Canada, First Nations) 
 Arab (includes Egyptian, Kuwait, Libyan) 
 West Asian (includes Afghan, Assyrian and Iranian) 
 Black (includes African, Nigerian, Somali) 
 Chinese 
 Filipino 
 Japanese 
 Korean 
 Latin American (includes Chilean, Costa Rican, Mexican) 
 South Asian (includes Bengladeshi, Punjabi, Sri Lankan) 
 South East Asian (includes Vietnamese, Cambodian, Malaysian) 
 White (Caucasian) 
 Other (specify: _______________________________) 
 Multiple cultural backgrounds (specify________________________) 
 
2. Who do you live with? 
 
 Family (spouse, children, etc.) 
 Alone  
 Other (specify:_____________________________________________________) 
 
 
3. How many people live in your house hold?  _____________ 
 
 
4. Do you live with someone who requires caregiving (e.g., ill spouse, grandchildren)? 
 
 Yes 
 No 
 
5. Which option best matches your work status? 
 Employed Full-time (that is 35 or more hours per week) 
 Employed Part-time  (that is less than 35 hours per week) 
 Self-employed (primary occupation) 
 Unemployed, but looking for work 
 Student 
 Retired 
 Not in the paid workforce (homemaker, unemployed, not looking for work) 
6. What is your marital status? 
 
 Single 
SECTION A: ABOUT YOU 
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 Married or equivalent (i.e., common law, same sex) 
 Separated or equivalent 
 Widowed 
 
7. What is the highest level of education you have completed? 
 
 Less than high school (no certificates, diplomas or degrees) 
 High school graduation certificate 
 Trades certificate 
 College certificate or diploma: a certificate from a community college, CEGEP, 
school of nursing, theological college or private college  
 University: a certificate below the bachelor’s level, bachelor’s degree, certificate 
above the bachelor level, master’s degree, earned doctorate or a professional 
degree in medicine, dentistry, veterinary medicine or optometry 
 
8. How much did you earn before taxes and other deductions, during the past 12 months? 
 
 Less than $5,000 
 $5,000 through $11,999 
 $12,000 through $15,999 
 $16,000 through $24,999 
 $25,000 through $34,999 
 $35,000 through $49,999 
 $50,000 through $74,999 
 $75,000 through $99,999 
 $100,000 and greater 
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Date: 
 
 
Participant Name 
Address 
RE: ECO-PCR Study: Exercise Maintenance in Men and Women Post-Cardiac 
Rehabilitation  
 
Dear Salutation –Participant Name,  
 
I am writing to request that you complete the enclosed survey for our research study on exercise after 
cardiac rehabilitation in patients with coronary artery disease (CAD), the study that you consented to 
participate in 6/18 months ago at the end of your cardiac rehabilitation program. We very much 
appreciate the time and effort you have put into helping us with this study and hope that you will be 
willing to complete this questionnaire. 
 
This survey, like the previous one, requests information about your physical activity, quality of life, 
risk factors and health care costs.  Enclosed is a pre-addressed and stamped envelope in which you can 
return the completed survey.   
 
If you have any questions regarding the survey or the study please feel free to contact the study 
coordinator at _________.  
 
We want to stress that your participation in this study is completely voluntary, and will not impact the 
care or services you or your family receive.  Please know that your help would be greatly appreciated 
and any information you could give us would further aid us in improving the quality of life for patients 
after cardiac rehabilitation, such as yourself. 
 
Thank you for your consideration. 
 
Sincerely,  
 
 
 
ECO-PCR Study Investigator 
York University & University Health Network 
              
                                          
 
 
 
 
 
 
 
 
 
 
APPENDIX E: 26-week cover-letter 
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ECO-PCR Telephone Script 
12 month Assessment  
Hello, my name is < insert name_>, and I am contacting you regarding the ECO-PCR study from the 
University Health Network. Is <participant name> available?  
Hello. I am calling about the ECO-PCR study, where we have been tracking the exercise patterns of 
our cardiac rehab graduates. It is time for your final 52 week assessment. This involves a stress test, 
filling out a survey, and wearing an accelerometer for 9 days.  
I mailed a “pulse check” form to you. The main purpose of this form is to allow you to get a free 
stress test. The doctor needs to verify that there are no health concerns in doing the stress test. 
Have you received the form in your mail?  
If yes: Great. Have you been able to schedule an appointment to see your doctor to get the form 
completed? Then the doctor can fax it to the cardiac rehab program. The fax number is on the form.  
If yes: The cardiac rehab program will contact you by phone when they receive the faxed form. 
They will schedule the stress test with you. They will let me know when you are coming in, 
and I will meet with you as well. Just like your 6 month assessment, I will take your blood 
pressure, heart rate, weight, height and waist circumference. I will also provide you a final 
survey to complete, and provide you with an accelerometer to wear for the following 9 days.  
Please bring a few things along with you:  
1. You medication bottles, so we can record your medication 
2. The “costing diary” if you received one 
3. Your “participant journal” if you received one 
4. Your pedometer that was provided at the beginning of the study. 
 
We will pay for your parking.  
<If patient is from _________: give them directions to the _________and explain about parking> 
If patient says no: My apologies. I will mail you the form right away.  
Do you have an email address?  
If yes: I could scan and email it to you.  
If no: let me just confirm your mailing address with you.  
 
If you have any question, please contact me at _________. Do you have a pen handy? I can repeat that 
number. If you prefer to reach me via email, my email address is _________. 
Thank you for your time and have a nice day.  
 
Voice Mail Script 
This is <researcher name > call from the ECO-PCR study at University Health Network, about 
exercise after cardiac rehab. I am calling to arrange your final 12 month assessment. I mailed you a 
“pulse check” form that you can take to your doctor to sign for your free stress test. I am calling to see 
if you received it, and if you had any questions about the assessment process. Do you have a pen 
handy? I can be reached at _________. REPEAT PHONE NUMBER AND EMAIL ADDRESS. 
Thank you. 
 
52 Wk Assessment Reminder Call 
Hello, my name is < insert name_>, and I am contacting you regarding the ECO-PCR study from the 
University Health Network. Is <participant name> available?  
Hello. I am calling about the ECO-PCR study, where we have been tracking the exercise patterns of 
our cardiac rehab graduates. This is a reminder that your stress test and final assessments are scheduled 
on <day of week> <month> <day of month> at <time>. I will be there as well to take your measures 
and give you your survey and pedometer.  
Please remember to bring:  
1. You medication bottles, so we can record your medication 
APPENDIX F: 52-week telephone script 
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2. The “costing diary” if you received one 
3. Your “participant journal” if you received one 
4. Your pedometer that was provided at the beginning of the study. 
 
Did you have any questions?  
If they say they need to re-schedule, provide contact information: _________. 
Okay. Thanks in advance, and I will look forward to meeting with you on <day>.  
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DATE COMPLETED:(dd/mm/yyyy)_____________________            Participant #___________ 
 
 
 
APPENDIX G: ECO-PCR Study 
Follow-up (26-week) Survey 
 
 
 
 
Instructions for completing the survey questions appear at the beginning of 
each section. 
 
Please seal your completed questionnaire in the envelope provided, and 
return it to the study coordinator. 
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1. Mobility 
 
 I have no problems in walking about 
 
 I have some problems in walking about 
 
 I am confined to bed 
 
 
2. Self-Care 
 
 I have no problems with self-care 
 
 I have some problems washing or dressing myself 
 
 I am unable to wash or dress myself 
 
 
3. Usual Activities (e.g. work, study, housework, family or leisure activities) 
 
 I have no problems with performing my usual activities 
 
 I have some problems with performing my usual activities 
  I am unable to perform my usual activities 
 
4. Pain/Discomfort 
 
 I have no pain or discomfort 
 
 I have moderate pain or discomfort 
 
 I have extreme pain or discomfort 
 
 
5. Anxiety/Depression 
 
 I am not anxious or depressed 
 
 I am moderately anxious or depressed 
 
 I am extremely anxious or depressed 
 
 
2 P.Kind. The EuroQol instrument: An index of health related quality of life. Quality of life and PharmacoEconomics in clinical trials. 
Second edition, edited by B.Spiker. Lippincott-Raven Publishers. Philadelphia 1996. 
 
 
 
 
 
 
SECTION C: YOUR QUALITY OF LIFE 
Instructions:  By placing a check-mark in one box in each group below, please indicate which statements best 
describe your own state of health today. 2 
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Please record all medications, prescribed by a health professional or bought over-the-counter, that you used 
DURING THE LAST 6 MONTHS FOR CARDIOVASCULAR HEALTH.  
Include medications taken for heart disease and its problems (e.g., pain), or problems caused by treatment (e.g. 
loss of sexual function).  
 
Write the dose used each time (e.g. two 5 mg pills=10 mg) and the number of times used each day. If you used it 
less often than once per day (e.g., an injection once every 4 weeks), please write this in the space after "Times 
taken/used per day". If you used more than 6 medications, please write them on the back page.  We suggest that 
you put the medications you have at home in front of you while you answer these questions. Remember to include 
herbal medicine, skin creams, drops, needles, etc., as well as pills. 
 
 I used NO medications during the last 6 months. 
                                                                                      
1. Medication: _______________________________________ 
 
Dose (each time taken/used) :________    Times taken/used per day:________  
 
2. Medication: _________________________________________________ 
 
Dose (each time taken/used) :_______      Times taken/used per day:________     
 
3. Medication: _______________________________________________ 
 
Dose (each time taken/used) :_______     Times taken/used per day:_______      
 
4. Medication: ______________________________________________________ 
 
Dose (each time taken/used) :_______     Times taken/used per day:________   
 
5. Medication: ________________________________________________ 
 
Dose (each time taken/used) :________     Times taken/used per day:______ 
 
     6. Medication: _________________________________________________ 
 
Dose (each time taken/used) :_______   Times taken/used per day:__________      
 
    7. Medication: _________________________________________________ 
 
Dose (each time taken/used) :_______   Times taken/used per day:__________      
 
 
8.  How much of your own money did you spend in the last 12 months, with no   
     reimbursement, for all of your medications?    $ _________________ 
 
 
 
 
 
SECTION M: YOUR MEDICATIONS 
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We would like to know about the health professionals you saw during the last 6 months BECAUSE OF YOUR 
CARDIOVASCULAR HEALTH. It will be easier to answer if you refer to a calendar or appointment list on which 
you record your appointments. If you did not keep a record, try to remember if any appointments were on or near 
special days, such as your birthday, or the day of a social event. Please answer the questions below by entering 
the number of times in the past 6 months that you have: 
 
1. How much did you earn before taxes and other deductions, during the past 12 months? 
 
 Less than $5,000 
 $5,000 through $11,999 
 $12,000 through $15,999 
 $16,000 through $24,999 
 $25,000 through $34,999 
 $35,000 through $49,999 
 $50,000 through $74,999 
 $75,000 through $99,999 
 $100,000 and greater 
 
  Number of times  
2. Seen your family doctor 
 
________ 
3. Seen a heart specialist 
 
________ 
4. Gone to the Emergency Department  
 
________ 
5. Been admitted to the hospital  
 
________ 
 
6. Have you experienced any of the following heart problems or procedures in the last 6 months? (Please check 
 all that apply): 
 Heart Attack          
 Angina          
 Angioplasty (stent)    
 Bypass Surgery           
 Valve Surgery           
 Heart Failure  
 Heart transplant  
 Pacemaker or implantable cardiovascular defibrillator 
 Stroke  
 Peripheral Vascular Disease 
 Ablation 
 Left ventricular assist device 
 Other, please specify: ______________________________________ 
 None of the above 
 
 
 
 
 
SECTION N:  CARE & COSTS 
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7. Have you experienced any of the following diagnostic tests in the last 6 months? (Please check  all that 
apply):  
 X-Ray 
 Electrocardiogram (ECG) 
 Blood test 
 Urine test 
 CT Scan 
 Echocardiogram 
 Stress Test 
 Other, please specify: ______________________________________ 
 None of the above 
 
8. How much of your own money, in total, did you pay for these health care visits (eg., transportation, parking, 
food, lodging), including the money paid by anyone who accompanied you?  
 None       OR enter amount:    $_________ 
    
9. How much time was associated with these health care visits (include travel, waiting, etc.)?  
 
________hours in total 
 
10. In the last 6 months, who USUALLY accompanied you on these health care visits? Check ( ) all that apply.  
 Nobody; I usually went by myself 
 Partner 
 Son, daughter, or grandchild 
 Sister, brother, friend, or neighbour 
 Volunteer 
 Paid homemaker or caregiver 
 Other, please specify_____________________________________ 
 
10b. This person’s age is: ___________years.   
 
10c. This person is:    Male  OR     Female 
 
 
11. Please describe your current smoking status:  
 
a.  Have you ever smoked cigarettes daily?       Yes        No (if no, move to Q12) 
 
       b.  At the present time, do you smoke cigarettes?     Every day     Occasionally     Not at all    
  
      c.  If not at all, when did you stop smoking?  ________________ (month and year) 
 
 
12. In the past 6 months, have you had a change in your: 
 
(a) Place of Residence?      Yes        No If yes, please describe:  _________________________ 
 
(b) Work Status?      Yes          No If yes, please describe: _________________________ 
 
13. What best describes your occupation at the time of your heart diagnosis?  
 Professional, technical and related (teachers, lawyers, physicians, engineers) 
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 Managers, administrators or proprietors (manager, real estate agent, postmasters) 
 Clerical and related (secretaries, clerks, mail carriers) 
 Sales occupations (sales person, demonstrator, agent or broker) 
 Service occupations (police, cook, hairdresser) 
 Skilled crafts, repairer and related (carpenters, telephone line workers) 
 Equipment or vehicle operators and related (drivers, brakemen) 
 Laborers (helpers, longshoremen, warehouse workers) 
 Farmers (owners, managers, operators, tenants) 
 Military 
 Homemaker 
 Not working 
 Retired 
 Other, please describe: ________________________________________________ 
 
 
14.  Did heart disease or its treatment lead you to retirement or disability? 
 Yes 
 No 
 Not applicable 
 
15. How many days of work did you miss since you graduated from cardiac rehabilitation? ______ days 
 
 
16. If you are not currently working, how many days were you unable to perform your usual activities?  ____ days 
 
 
17. Have you EVER seen a health professional or had treatment for heart disease  
     OUTSIDE of Ontario?  
NO - Go to Question 18 
YES ……continue below 
Where (city, province, state, country):____________________________________ 
When (month and year): From____________________ to___________________  
 
Type(s) of health professional seen:___________________________________ 
_________________________________________________________________ 
Treatment(s) you received:_____________________________________________ 
___________________________________________________________________ 
 
If you had other heart disease treatment outside of Ontario, please tell us about it on the back of this page. 
Describe where, when, who and treatments received. 
 
 
18. Equipment (aids, devices, household items) bought during the last 6 months  
       Please list all items you bought during the last 6 months for a problem related to heart disease, and the 
amount of your own money, if any, that you paid for each.  
 
I bought NO equipment in the last 6 months because of heart disease.                                 
Please go to Question 19. 
 
1. Item_________________________________  Cost to you: $___________ 
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2. Item_________________________________  Cost to you: $___________ 
 
3. Item_________________________________  Cost to you: $___________ 
 
4. Item_________________________________  Cost to you: $___________ 
 
5. Item_________________________________  Cost to you: $___________ 
 
6. Item_________________________________  Cost to you: $___________ 
 
 
19. Community services used during the last 6 months  
 Please list any community services (e.g., home care, meals-on-wheels, transportation) you used in the last 6 
months because of a disability RELATED TO YOUR HEART DISEASE. Please record the number of times that 
you used each and how much you paid of your own money for each service. 
 
I used NO community services in the last 6 months because of heart disease. 
Please go to Question 20. 
 
OR list the services you used IN THE LAST 6 MONTHS below 
 
1. Service_______________________  Times used____   Total Cost to you: $______ 
 
2. Service_______________________ Times used_____ Total Cost to you: $______ 
 
3. Service______________________   Times used_____Total Cost to you: $_______ 
 
4. Service_______________________ Times used_____Total Cost to you: $_______ 
 
5. Service_______________________ Times used_____Total Cost to you: $_______ 
 
 
20. Difficulty working 
During the past 6 months, did you have any difficulty working at your paid employment because of  your heart 
disease or its treatment? 
 
 I was unemployed or retired during the past 6 months. 
 Please go to Question 21. 
 NO, no difficulty working because of heart disease 
 Please go to Question 21. 
 
 YES, I had difficult working  
        Total time you had difficulty working:  ______days and/or __________  hours 
 
By approximately what percent was your working capacity reduced during this time? 
                    _____________% 
 
 
21. Household chores 
 During the past 6 months, were you unable to do chores around the house (such as housecleaning, shovelling 
snow, running errands) because of  your heart disease? 
 
 I cannot do chores because of another illness or disability, or I do not have any household chores to do  
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Please go to Question 22. 
 NO, I had no problem doing chores.  
Please go to Question 22. 
 
YES, I was unable to do chores because of heart disease. 
 
Total time you could not do chores:   ____________days and/or ___________hours  
Total amount of time that other people did chores for you in the last 6 months, without pay from you:  
     None  OR    _________days and/or ____________hours 
 
Total amount of your own money you paid people to do chores for you in the last 6 months:  
     None  OR   $ ____________ 
 
 
22. Leisure activities 
During the past 6 months, did you have any problems participating in your usual leisure activities because of  
your heart disease or its treatment?  
 
 NO, I had no problems with leisure activities because of heart disease in the last 6 months  
   Please go to Question 23 
 
 YES, I had problems with leisure activities because of heart disease in the last 6 months : 
 
Total amount of time you had difficulty with leisure activities in the last 6 months:  
________days and/or ___________hours.  
                 
 
23. Do you have any health care or medical insurance other than that provided by OHIP or the Ontario Drug 
Benefit Plan?    
  YES      NO 
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DATE COMPLETED: (dd/mm/yyyy) ______________________ 
                                                                                                                      Participant #_____________ 
 
 
APPENDIX H: ECO-PCR Study 
Follow-Up (52-week) Survey 
 
 
 
 
Instructions for completing the survey questions appear at the beginning of 
each section. 
 
Please seal your complete questionnaire in the envelope provided, and 
return it to the study coordinator. 
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1. Mobility 
 
 I have no problems in walking about 
 
 I have some problems in walking about 
 
 I am confined to bed 
 
 
2. Self-Care 
 
 I have no problems with self-care 
 
 I have some problems washing or dressing myself 
 
 I am unable to wash or dress myself 
 
 
3. Usual Activities (e.g. work, study, housework, family or leisure activities) 
 
 I have no problems with performing my usual activities 
 
 I have some problems with performing my usual  
activities 
 I am unable to perform my usual activities 
 
4. Pain/Discomfort 
 
 I have no pain or discomfort 
 
 I have moderate pain or discomfort 
 
 I have extreme pain or discomfort 
 
 
5. Anxiety/Depression 
 
 I am not anxious or depressed 
 
 I am moderately anxious or depressed 
 
 I am extremely anxious or depressed 
 
 
 
 
2 P.Kind. The EuroQol instrument: An index of health related quality of life. Quality of life and PharmacoEconomics in clinical trials. 
Second edition, edited by B.Spiker. Lippincott-Raven Publishers. Philadelphia 1996. 
SECTION C: YOUR QUALITY OF LIFE 
 
Instructions:  By placing a check-mark in one box in each group below, please indicate which statements best 
describe your own state of health today. 2 
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Please record all medications, prescribed by a health professional or bought over-the-counter, that you used 
DURING THE LAST 6 MONTHS FOR CARDIOVASCULAR HEALTH.  
Include medications taken for heart disease and its problems (e.g., pain), or problems caused by treatment (e.g. 
loss of sexual function).  
 
Write the dose used each time (e.g. two 5 mg pills=10 mg) and the number of times used each day. If you used it 
less often than once per day (e.g., an injection once every 4 weeks), please write this in the space after "Times 
taken/used per day". If you used more than 6 medications, please write them on the back page.  We suggest that 
you put the medications you have at home in front of you while you answer these questions. Remember to include 
herbal medicine, skin creams, drops, needles, etc., as well as pills. 
 
 I used NO medications during the last 6 months. 
                                                                                      
1. Medication: _______________________________________ 
 
Dose (each time taken/used) :________    Times taken/used per day:________  
 
2. Medication: _________________________________________________ 
 
Dose (each time taken/used) :_______      Times taken/used per day:________     
 
3. Medication: _______________________________________________ 
 
Dose (each time taken/used) :_______     Times taken/used per day:_______      
 
4. Medication: ______________________________________________________ 
 
Dose (each time taken/used) :_______     Times taken/used per day:________   
 
5. Medication: ________________________________________________ 
 
Dose (each time taken/used) :________     Times taken/used per day:______ 
 
6. Medication: _________________________________________________ 
  
Dose (each time taken/used) :_______   Times taken/used per day:__________      
 
    7. Medication: _________________________________________________ 
 
Dose (each time taken/used) :_______   Times taken/used per day:__________      
 
 
 
8.  How much of your own money did you spend in the last 6 months, with no   
     reimbursement, for all of your medications?     $ _________________ 
  
SECTION M: YOUR MEDICATIONS 
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We would like to know about the health professionals you saw during the last 6 months BECAUSE OF YOUR 
CARDIOVASCULAR HEALTH. It will be easier to answer if you refer to a calendar or appointment list on which 
you record your appointments. If you did not keep a record, try to remember if any appointments were on or near 
special days, such as your birthday, or the day of a social event. Please answer the questions below by entering 
the number of times in the past 6 months that you have: 
 
1. How much did you earn before taxes and other deductions, during the past 12 months? 
 
 Less than $5,000 
 $5,000 through $11,999 
 $12,000 through $15,999 
 $16,000 through $24,999 
 $25,000 through $34,999 
 $35,000 through $49,999 
 $50,000 through $74,999 
 $75,000 through $99,999 
 $100,000 and greater 
 
  Number of times  
2. Seen your family doctor 
 
________ 
3. Seen a heart specialist 
 
________ 
4. Gone to the Emergency Department  
 
________ 
5. Been admitted to the hospital  
 
________ 
 
6. Have you experienced any of the following heart problems or procedures in the last 6 months? (Please check 
 all that apply): 
 Heart Attack          
 Angina          
 Angioplasty (stent)    
 Bypass Surgery           
 Valve Surgery           
 Heart Failure  
 Heart transplant  
 Pacemaker or implantable cardioverter defibrillator 
 Stroke  
 Peripheral Vascular Disease 
 Ablation 
 Left ventricular assist device 
 Other, please specify: ______________________________________ 
 None of the above 
 
 
 
 
SECTION N:  CARE & COSTS 
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7. Have you experienced any of the following diagnostic tests in the last 6 months? (Please check  all that 
apply):  
 X-Ray 
 Electrocardiogram (ECG) 
 Blood test 
 Urine test 
 CT Scan 
 Echocardiogram 
 Stress Test 
 Other, please specify: ______________________________________ 
 None of the above 
 
8. How much of your own money, in total, did you pay for these health care visits (eg., transportation, parking, 
food, lodging), including the money paid by anyone who accompanied you?  
 None       OR enter amount:    $_________ 
    
9. How much time was associated with these health care visits (include travel, waiting, etc.)?  
 
________hours in total 
 
10. In the last 6 months, who USUALLY accompanied you on these health care visits? Check ( ) all that apply.  
 Nobody; I usually went by myself 
 Partner 
 Son, daughter, or grandchild 
 Sister, brother, friend, or neighbour 
 Volunteer 
 Paid homemaker or caregiver 
 Other, please specify_____________________________________ 
 
10b. This person’s age is: ___________years.   
 
10c. This person is:    Male  OR     Female 
 
 
11. a. Have you ever smoked cigarettes daily?       Yes        No  (if no, move to Q12) 
 
      b.  At the present time, do you smoke cigarettes?     Every day     Occasionally     Not at all    
  
      c.  If not at all, when did you stop smoking?  ________________ (month and year) 
 
 
 
12. In the past 6 months, have you had a change in your: 
 
(a) Place of Residence?      Yes        No If yes, please describe:  _________________________ 
 
(b) Work Status?      Yes          No If yes, please describe: _________________________ 
 
 
13. What best describes your occupation at the time of your heart diagnosis?  
 Professional, technical and related (teachers, lawyers, physicians, engineers) 
 Managers, administrators or proprietors (manager, real estate agent, postmasters) 
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 Clerical and related (secretaries, clerks, mail carriers) 
 Sales occupations (sales person, demonstrator, agent or broker) 
 Service occupations (police, cook, hairdresser) 
 Skilled crafts, repairer and related (carpenters, telephone line workers) 
 Equipment or vehicle operators and related (drivers, brakemen) 
 Laborers (helpers, longshoremen, warehouse workers) 
 Farmers (owners, managers, operators, tenants) 
 Military 
 Homemaker 
 Not working 
 Retired 
 Other, please describe: ________________________________________________ 
 
 
14.  Did heart disease or its treatment lead you to retirement or disability? 
 Yes 
 No 
 Not applicable 
 
15. How many days of work did you miss since you graduated from cardiac rehabilitation? ______ days 
 
16. If you are not currently working, how many days were you unable to perform your usual activities?       
 
            _____ days 
17. Have you EVER seen a health professional or had treatment for heart disease  
     OUTSIDE of Ontario?  
NO - Go to Question 18 
YES ……continue below 
Where (city, province, state, country):____________________________________ 
When (month and year): From____________________ to___________________  
 
Type(s) of health professional seen:___________________________________ 
_________________________________________________________________ 
Treatment(s) you received:_____________________________________________ 
___________________________________________________________________ 
 
If you had other heart disease treatment outside of Ontario, please tell us about it on the back of this page. 
Describe where, when, who and treatments received. 
 
 
 
18. Equipment (aids, devices, household items) bought during the last 6 months  
       Please list all items you bought during the last 6 months for a problem related to heart disease, and the 
amount of your own money, if any, that you paid for each.  
 
I bought NO equipment in the last 6 months because of heart disease.                                 
Please go to Question 19. 
 
1. Item_________________________________  Cost to you: $___________ 
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2. Item_________________________________  Cost to you: $___________ 
 
3. Item_________________________________  Cost to you: $___________ 
 
4. Item_________________________________  Cost to you: $___________ 
 
5. Item_________________________________  Cost to you: $___________ 
 
6. Item_________________________________  Cost to you: $___________ 
 
 
19. Community services used during the last 6 months  
 Please list any community services (e.g., home care, meals-on-wheels, transportation) you used in the last 6 
months because of a disability RELATED TO YOUR HEART DISEASE. Please record the number of times that 
you used each and how much you paid of your own money for each service. 
 
I used NO community services in the last 6 months because of heart disease. 
Please go to Question 20. 
 
OR list the services you used IN THE LAST 6 MONTHS below 
 
1. Service_______________________  Times used____   Total Cost to you: $______ 
 
2. Service_______________________ Times used_____ Total Cost to you: $______ 
 
3. Service______________________  Times used_____Total Cost to you: $_______ 
 
4. Service_______________________ Times used_____Total Cost to you: $_______ 
 
5. Service_______________________ Times used_____Total Cost to you: $_______ 
 
 
20. Difficulty working 
 During the past 6 months, did you have any difficulty working at your paid employment because of your heart 
disease or its treatment? 
 
I was unemployed or retired during the past 6 months. 
 Please go to Question 21. 
 NO, no difficulty working because of heart disease 
 Please go to Question 21. 
 YES, I had difficult working  
         
Total time you had difficulty working:  ______days and/or __________  hours 
 
By approximately what percent was your working capacity reduced during this time? 
                    _____________% 
 
21. Household chores 
 During the past 6 months, were you unable to do chores around the house (such as housecleaning, shovelling 
snow, running errands) because of  your heart disease? 
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Tracking my Health 
and Expenses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX I: Costing Diary 
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 Instructions: We would like to know information regarding your health and related expenses. In the 
table below, please record the date, event details, if the event required you to spend any of your own 
money, and the amount of your time which was spent.  We are especially interested in hearing about: 
 Visits to your family doctor, heart specialist, or the hospital and if any diagnostic tests were 
performed  
 Any changes to your work status 
 Missed work days due to your cardiovascular health 
 Days you were unable to perform your usual activities or household chores due to your 
cardiovascular health 
 Equipment purchases related to your cardiovascular health (i.e. aids, devices, household items, 
exercise equipment) 
 Community services used due to your cardiovascular health (i.e. food delivery services, 
exercise classes) 
Date Event Details Cost to 
you 
Time 
Spent 
Ex: Sept 10, 
2012 
Visited the Ottawa Heart Institute and completed a 
stress test on the treadmill 
13$ for 
parking 
1 hour 
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Contact Format Duration 
(min) 
Timing relative 
to CR 
completion 
(weeks) 
Content Targeted barriers/facilitators 
1 Introduction 
Session 
(in person) 
60 Baseline  Introduction to intervention tools and counseling 
teleconferences 
 Establish standards and identify potential barriers for 
exercise adherence 
 Complete action/coping planning exercise (Goal Setting) 
 Complete exercise activity inventory 
 Provide activity diary (Self-Monitoring) 
 Provide pedometer (Self-Monitoring) 
 Create awareness for PCR community programs and 
provide list for Heart Wise exercise programs in community 
 Exercise safety 
 
 Knowledge/Awareness 
 Confidence 
 Motivation 
 Action planning 
 Linkages with approved community 
programs 
 Social Support 
 Home exercise equipment 
 Self-monitoring 
2 Small group 
counseling 
teleconference 
60 1 - 3  Review activity diary 
 Identify barriers to exercise adherence experienced to date 
 Brainstorm solutions to barriers in group 
 Complete coping planning exercise 
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
 Confidence 
 Motivation 
 Action planning 
 Social support 
 Physical symptoms 
 
3 Community 
Program 
Demonstrations 
(multiple 
opportunities) 
60-90 Every 2-3 
weeks for 52 
weeks 
 Facilitator-lead tour of community exercise facility and 
orientation to Heart Wise Exercise programs occurring at 
that location 
 Demonstration of individual exercise opportunities using 
facility equipment 
 Overview of program registration procedures 
 Facilitation of physician referral for interested participants 
 Motivation 
 Social support 
 Convenient exercise options 
APPENDIX J: Intervention Summary Table 
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for program or facility enrollment  
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
4 Small group 
counseling 
teleconference 
60 13  Review activity diary 
 Identify barriers to exercise adherence experienced to date 
 Brainstorm solutions to barriers in group 
 Complete coping planning exercise 
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
 Confidence 
 Motivation 
 Action planning 
 Social support 
 Physical symptoms 
 
5 Personal 
telephone call 
15-30 20  Review activity diary 
 Assess confidence and motivation 
 Discuss barriers and solutions 
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
 Confidence 
 Motivation 
 Social support 
 Physical symptoms 
6 Small group 
counseling 
teleconference 
60 26  Review activity diary 
 Identify barriers to exercise adherence experienced to date 
 Brainstorm solutions to barriers in group 
 Complete coping planning exercise 
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
 Confidence 
 Motivation 
 Action planning 
 Social support 
 Physical symptoms 
7 Personal 
telephone call 
15-30 34  Review activity diary 
 Assess confidence and motivation 
 Discuss barriers and solutions 
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
 Confidence 
 Motivation 
 Social support 
 Physical symptoms 
8 Small group 
counseling 
teleconference 
60 39  Review activity diary 
 Identify barriers to exercise adherence experienced to date 
 Brainstorm solutions to barriers in group 
 Confidence 
 Motivation 
 Action planning 
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CAD – Coronary Artery Disease 
 
 
 
 
 Complete coping planning exercise 
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
 Social support 
 Physical symptoms 
9 Personal 
telephone call 
15-30 45  Review activity diary 
 Assess confidence and motivation 
 Discuss barriers and solutions 
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
 Confidence 
 Motivation 
 Social support 
 Physical symptoms 
10 Small group 
counseling 
teleconference 
60 50  Review activity diary 
 Identify barriers to exercise adherence experienced to date 
 Brainstorm solutions to barriers in group 
 Complete coping planning exercise 
 Discuss past successes and failures 
 Elicit personal views and discuss benefits of exercise for 
CAD management 
 
 Confidence 
 Motivation 
 Action planning 
 Social support 
 Physical symptoms 
